WO2005061704A1 - 癌の予防・治療剤 - Google Patents
癌の予防・治療剤 Download PDFInfo
- Publication number
- WO2005061704A1 WO2005061704A1 PCT/JP2004/019724 JP2004019724W WO2005061704A1 WO 2005061704 A1 WO2005061704 A1 WO 2005061704A1 JP 2004019724 W JP2004019724 W JP 2004019724W WO 2005061704 A1 WO2005061704 A1 WO 2005061704A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- protein
- amino acid
- acid sequence
- present
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
Definitions
- the present invention relates to a substance (eg, an antibody) that inhibits the binding between the SEMA4B protein or the like and the P1eXinB1 protein or the like, the SEMA4B protein or the like, and the P1eXinB1 protein.
- the present invention relates to a substance that inhibits the activity (eg, an antibody), a prophylactic / therapeutic agent or apoptosis-promoting agent containing the substance, and a screening for a cancer-preventive / therapeutic agent or an apoptosis-promoting agent.
- Recent advances in microarray and oligonucleotide array technologies have enabled comprehensive analysis of gene expression. It has also been predicted that the disease state of cancer can be evaluated using gene microarray profiling data. In fact, it has been reported that leukemia can be classified by gene expression profile in leukemia. By clarifying the gene expression profiles of individual cancer tissues and accumulating the classifications, it is possible to predict the responsiveness to specific cancer treatments and to discover new drug discovery target proteins for specific cancers. It is considered possible. Specifically, when the expression of a certain protein is increased in a certain cancer, (i) the expression level is reduced for patients newly diagnosed as positive for antigen, (ii) And (lii) eliciting a host immune response to the protein to induce antitumor activity.
- Semaphorin family is a large protein family composed of both secreted and membrane-bound molecules, with at least 19 species in vertebrates and three species in invertebrates. A gene has been reported (Cell 97, 551-552, 1999).
- Semaphorin famili is known to be involved in a wide range of neurogenesis processes, such as nerve axon guidance and synapse formation.
- Semaphorin 3B and Semaphorin 3F derived from human belonging to Semaphorin family are reported as tumor suppressor genes (Proc. Natl Acad. Sci. USA 98, 13954-13959, 2001, Cancer Res. 62, 542). -546, 2002, Cancer Res. 62, 2637-2643, 2002).
- Human Semaphorin 3C has been reported to be upregulated in human lung cancer tissues (J. Surg. Oncol. 72, 18-23, 1999, Proc. Natl Acad. Sci. USA 94, 14713-14718, 1997). It has been reported that human Semaphorin 3E is expressed in metastatic cells (Cancer Res. 58, 1238-1244, 1998).
- SEMA4B Human Semaphorin 4B
- SEMA4D Human Semaphorin 4D
- SEMA4D Human Semaphorin 4D
- SEMA4D Human Semaphorin 4D
- hundreds of nucleotide sequences including SEMA4B and the like based on gene chip analysis can be used for lung cancer diagnosis or search for compounds for treating lung cancer (W002 / 86443). It has been reported that N0V7, which has 93% homology with SEMA4B at the amino acid level, is upregulated in cancer (TO 02/06329).
- WO 03/003906 discloses a method for diagnosing bladder cancer using a polynucleotide or polypeptide having a homology of 60% or more with SEMA4B or the like, an antibody, or a compound such as Starry Jung that regulates a bladder cancer-related protein.
- the ligand of human PlexinBl (hereinafter sometimes abbreviated as PlexinBl; GenBank: AB007867) is SEMA4D (Cell, Vol. 99, pp. 71-80, 1999), and PlexinBl is human hepatocyte proliferation. Forms a complex with the factor (HGF) receptor. When stimulated with SEMA4D, both PlexinBl and HGF receptor are phosphorylated, and cell proliferation is promoted (Nature Cell Biol. Vol. 4, 720 Pp. 724, 2002).
- the present inventors have conducted intensive studies to solve the above-mentioned problems, and found that SEMA4B binds to PlexinBl, and that inhibition of the binding of both promotes apoptosis of cancer cells, SEMA4B was found to inhibit the binding of SEMA4B to PlexinBl. As a result of further studies based on this finding, the present invention has been completed.
- a protein containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7, or SEQ ID NO: 10 or a portion thereof Inhibits the binding of the peptide or a salt thereof to a protein or a partial peptide or a salt thereof containing an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO: 26 Substance,
- the substance according to the above (1) which is an antibody having an activity of neutralizing cell proliferation stimulation
- the antibody is a monoclonal antibody, the substance according to the above (2) or (3), (5) a preventive or therapeutic agent for cancer comprising the substance according to the above (1),
- a cancer cell apoptosis promoter comprising the substance according to the above (1)
- a cancer cell growth inhibitor comprising the substance according to (1)
- a cancer cell growth inhibitor comprising a substance that inhibits the activity of a partial peptide or a salt thereof;
- a prophylactic or therapeutic agent for cancer comprising a substance that inhibits the activity of a partial peptide or a salt thereof,
- An agent for promoting apoptosis of cancer cells comprising a substance that inhibits the activity of a partial peptide or a salt thereof;
- the substance inhibits a protein containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 26, a partial peptide thereof, or a phosphoric acid salt thereof
- a prophylactic or therapeutic agent for cancer comprising the substance of the above-mentioned [9], (1 2a) Prevention and treatment of cancer comprising the substance described in (9a) above; (13) Agent for promoting apoptosis of cancer cells comprising the substance described in (9) above; 3a] an agent for promoting apoptosis of cancer cells comprising the substance according to the above [9a]; [14] an agent for suppressing proliferation of cancer cells comprising the substance according to the above [9];
- [15] (a) a protein containing an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7, or SEQ ID NO: 10 or a portion thereof A peptide or a salt thereof, and (b) a protein or a partial peptide or a salt thereof containing an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO: 26, A method for screening a substance that inhibits the binding between the protein (a) or its partial peptide or its salt and the protein (b) or its partial peptide or its salt of (b), [16] (a) a protein containing an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7, or SEQ ID NO: 10 or ( B ) a protein having the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 26, or a partial peptide or a salt thereof; A kit for screening
- SEQ ID NO: 26 characterized by using a protein containing an amino acid sequence identical or substantially identical to the amino acid sequence represented by 26, a partial peptide thereof or a salt thereof, SEQ ID NO: 26.
- SEQ ID NO: 26 wherein a gene containing a protein having the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 26 or a partial peptide thereof or a salt thereof is used.
- SEQ ID NO: 26 comprising a protein containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 26, a partial peptide thereof, or a salt thereof.
- a protein containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7 or SEQ ID NO: 10, or a protein thereof Inhibits the binding of a partial peptide or a salt thereof to a protein containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 26 or a partial peptide thereof or a salt thereof Cancer prevention / treatment method, cancer cell apoptosis promotion method and / or cancer cell growth suppression method,
- a cancer characterized by inhibiting the phosphorylation of a protein having the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 26 or a partial peptide thereof or a salt thereof Prevention and treatment of cancer, cancer cell apoptosis promotion method and / or cancer cell growth suppression method,
- a method for preventing or treating cancer which is characterized by inhibiting the activity of the partial peptide or a salt thereof, a method for promoting apoptosis of cancer cells, and / or a method for suppressing proliferation of cancer cells,
- [22a] The above-mentioned [22], which is an antibody that also recognizes a protein containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 26, a partial peptide thereof, or a salt thereof.
- the method described, [22b] a protein or a protein containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7 or SEQ ID NO: 10; The method according to the above (21a) using an antibody against the partial peptide or a salt thereof,
- the above-mentioned antibody [22] which is an antibody that also recognizes a protein having the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 26, a partial peptide thereof, or a salt thereof. b) the method described,
- [23] a method for preventing and treating cancer, a method for promoting apoptosis of cancer cells, and / or a method comprising administering to a mammal an effective amount of the substance described in [1] or [9].
- a method for inhibiting the growth of cancer cells
- a method for preventing and treating cancer a method for promoting apoptosis of cancer cells, which comprises administering an effective amount of a substance that inhibits the activity of a protein or partial peptide or salt thereof contained therein. Growth suppression method,
- SEQ ID NO: 1 SEQ ID NO: 4, SEQ ID NO: 7 for producing an agent for preventing or treating cancer, an agent for promoting apoptosis of cancer cells (or) an agent for suppressing the growth of cancer cells
- the present invention provides a use of a substance having the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 10 or a substance that inhibits the activity of a partial peptide or a salt thereof.
- a protein containing an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7 or SEQ ID NO: 10 (hereinafter referred to as the protein of the present invention or
- the protein used in the present invention may be referred to as a human warm-blooded animal (eg, guinea pig, rat, mouse, chick, egret, pig, sheep, pig, monkey, etc.) cells (eg, hepatocytes, hepatocytes, etc.).
- Splenocytes nerves Cells, glial cells, spleen i3 cells, bone marrow cells, mesangial cells, Langerhans cells, epidermal cells, epithelial cells, goblet cells, endothelial cells, smooth muscle cells, fibroblasts, fiber cells, muscle cells, fat cells, immune cells ( Examples: macrophages, T cells, B cells, natural killer cells, mast cells, neutrophils, basophils, eosinophils, monocytes), megakaryocytes, synovial cells, chondrocytes, bone cells, osteoblasts Osteoclasts, mammary gland cells, hepatocytes or stromal cells, or progenitor cells, stem cells or cancer cells of these cells) or any fibrous tissue where these cells are present, for example, brain, various parts of the brain (eg, , Olfactory bulb, amygdaloid nucleus, basal cerebral nucleus, hippocampus, thalamus, hypothalamus
- the amino acid sequence substantially the same as the amino acid sequence represented by SEQ ID NO: 1 is at least 95%, preferably at least about 98%, preferably at least 98% with the amino acid sequence represented by SEQ ID NO: 1.
- Examples include amino acid sequences having about 99% or more homology.
- Examples of the protein having an amino acid sequence substantially the same as the amino acid sequence represented by SEQ ID NO: 1 include, for example, an amino acid sequence substantially the same as the amino acid sequence represented by the aforementioned SEQ ID NO: 1 And a protein having substantially the same activity as the protein containing the amino acid sequence represented by SEQ ID NO: 1.
- the amino acid sequence substantially identical to the amino acid sequence represented by SEQ ID NO: 4 includes
- Examples of the protein containing an amino acid sequence substantially identical to the amino acid sequence represented by SEQ ID NO: 4 include, for example, amino acids substantially identical to the amino acid sequence represented by the aforementioned SEQ ID NO: 4
- a protein having a sequence and having substantially the same activity as a protein having an amino acid sequence represented by SEQ ID NO: 4 is preferred.
- the amino acid sequence substantially identical to the amino acid sequence represented by SEQ ID NO: 7 includes
- the protein containing an amino acid sequence substantially identical to the amino acid sequence represented by SEQ ID NO: 7 include, for example, an amino acid sequence substantially identical to the amino acid sequence represented by SEQ ID NO: 7 described above.
- the amino acid sequence substantially identical to the amino acid sequence represented by SEQ ID NO: 10 include an amino acid sequence having 99.9% or more homology with the amino acid sequence represented by SEQ ID NO: 10. No.
- Examples of the protein containing an amino acid sequence substantially identical to the amino acid sequence represented by SEQ ID NO: 10 include, for example, a protein substantially identical to the amino acid sequence represented by the aforementioned SEQ ID NO: 10
- a protein containing an amino acid sequence and having substantially the same activity as a protein containing an amino acid sequence represented by SEQ ID NO: 10 is preferred.
- substantially equivalent activities include, for example, the receptor binding activity used in the present invention (described later) and the phosphorylation inducing / promoting activity of the receptor used in the present invention.
- Substantially identical indicates that the properties are qualitatively (eg, physiologically or pharmacologically) identical. Therefore, the receptor binding activity used in the present invention and the phosphorylation inducing / promoting activity of the receptor used in the present invention are equivalent (eg, about 0.01 to 100 times, preferably about 0.1 to 10 times). (More preferably 0.5 to 2 times), but the quantitative factors such as the degree of activity and the molecular weight of the protein may be different.
- the binding activity can be measured according to a method known per se, for example, an EIA method, an immunoprecipitation method or a method analogous thereto.
- each of the protein used in the present invention and the receptor used in the present invention is expressed in animal cells as a tagged recombinant protein.
- the tag FLAG, His, V5, myc, HA and the like are used, and the tag added to the protein used in the present invention ( A tag different from tag A) and a tag (tag B) added to the receptor used in the present invention are used.
- the phosphorylation-inducing / promoting activity is measured according to a method known per se, for example, the method described in Methods in Enzymology, Vol. 200, pp. 98-107, 1991 or a method analogous thereto.
- the receptor used in the present invention with a tag eg, FLAG, His, V5, myc, HA, etc.
- a tag eg, FLAG, His, V5, myc, HA, etc.
- the cells After reaction with the protein to be prepared, the cells are disrupted, a cell-free extract is prepared, immunoprecipitated with an anti-tag antibody, and the amount of phosphorylated receptor used in the present invention is determined by It can be measured by a known method (eg, Western plotting method) using a tyrosine antibody or the like.
- Examples of the protein used in the present invention include: (1) (i) one or two or more amino acids in the amino acid sequence represented by SEQ ID NO: 1 (eg, about 1 to 50, preferably 1 to 30) Amino acid sequence in which about 1 to 10 amino acids have been deleted, more preferably about 1 to 10 amino acids, and still more preferably 1 to 5 amino acids, and (ii) one or more amino acid sequences represented by SEQ ID NO: 1.
- SEQ ID NO: 1 Two or more (for example, about 1 to 50, preferably about 1 to 30, more preferably about 1 to 10, and more preferably a number (1 to 5) amino acids to which amino acids are added)
- SEQ ID NO: 1 one or more amino acid sequences represented by SEQ ID NO: 1 (eg, about 1 to 50, preferably about 1 to 30, more preferably 1 to 10) Degree, more preferably number (1-5) amino acids, and (iv) SEQ ID NO: 1.
- amino acid sequence is inserted, deleted or substituted as described above,
- the position of the deletion or substitution is not particularly limited.
- protein used in the present invention include, for example, a protein containing an amino acid sequence represented by SEQ ID NO: 1, a protein containing an amino acid sequence represented by SEQ ID NO: 4, SEQ ID NO: 7 And a protein containing the amino acid sequence represented by SEQ ID NO: 10 and the like.
- a protein containing an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO: 26 is a human warm-blooded animal (for example, , Guinea pigs, rats, mice, chicks, rabbits, pigs, sheep, sheep cells, monkeys, etc.
- hepatocytes eg, hepatocytes, spleen cells, neurons, glial cells, glial cells, bone marrow cells, mesangial cells, Langerhans cells, epidermal cells, epithelial cells, goblet cells, endothelial cells, smooth muscle cells, fibroblasts, fibrous cells, muscle cells, adipocytes, immune cells (eg, macrophages, T cells, B cells, natural killer cells) , 'Mast cells, neutrophils, basophils, eosinophils, monocytes), megakaryocytes, synovial cells, chondrocytes, bone cells, osteoblasts, osteoclasts, breast cells Hepatocytes or stromal cells, or precursors of these cells, stem cells or cancer cells, or any tissue in which these cells are present, such as the brain, parts of the brain (eg, olfactory bulb, amygdala, Basal sphere, hippocampus, thalamus
- the amino acid sequence substantially the same as the amino acid sequence represented by SEQ ID NO: 26 includes about 50% or more, preferably about 60% or more, preferably the amino acid sequence represented by SEQ ID NO: 26. Is an amino acid sequence having a homology of about 70% or more, preferably about 80% or more, preferably about 90% or more, and preferably about 95% or more.
- Examples of the protein having an amino acid sequence substantially identical to the amino acid sequence represented by SEQ ID NO: 26 include, for example, an amino acid sequence substantially identical to the amino acid sequence represented by SEQ ID NO: 26 described above. And a protein having substantially the same activity as the protein having the amino acid sequence represented by SEQ ID NO: 26.
- substantially equivalent activities include, for example, the protein binding activity and the phosphorylating activity used in the present invention (eg, the activity of being phosphorylated by stimulation of the protein of the present invention).
- Substantially identical indicates that the properties are qualitatively (eg, physiologically or pharmacologically) equivalent. Therefore, it is preferable that the above-mentioned activities are equivalent (eg, about 0.01 to 100 times, preferably about 0.1 to 10 times, and more preferably 0.5 to 2 times).
- the quantitative factors such as the degree of these activities and the molecular weight of the protein may be different.
- the activity of phosphorylation is measured according to a method known per se, for example, the method described in Methods in Enzymology 200, pp. 98-107, 1991, or a method analogous thereto.
- a receptor eg, FLAG, His, V5, myc, HA, etc.
- a tag eg, FLAG, His, V5, myc, HA
- the amount of phosphorylated receptor used in the present invention can be quantified by a known method (eg, Western blot method) using an anti-phosphotyrosine antibody or the like.
- the receptor used in the present invention includes, for example, (i) represented by SEQ ID NO: 26 One or more (eg, about 1 to 50, preferably about 1 to 30, more preferably about 1 to 10, and more preferably about 1 to 5) (Ii) one or more amino acid sequences (for example, about 1 to 50, preferably about 1 to 30) in the amino acid sequence represented by SEQ ID NO: 26; Preferably about 1 to 10 amino acids, more preferably about 1 to 5 amino acids, and (iii) one or two amino acid sequences represented by SEQ ID NO: 26.
- More than one amino acid (for example, about 1 to 50, preferably about 1 to 30, more preferably about 1 to 10, and more preferably a number (1 to 5)) Amino acid sequence, (iv) one or two or more amino acids in the amino acid sequence represented by SEQ ID NO: 26 (for example, about 1 to 50, preferably 1 to 50) An amino acid sequence in which up to about 30, more preferably about 1 to 10, and even more preferably a number (1 to 5) amino acids are substituted with another amino acid, or (V) an amino acid obtained by combining them So-called muteins, such as proteins containing sequences, are also included.
- the position of the insertion, deletion or substitution is not particularly limited.
- receptor used in the present invention include, for example, a protein containing an amino acid sequence represented by SEQ ID NO: 26, and the like.
- the receptor used in the present invention may form a complex with a hepatocyte growth factor (HGF) receptor.
- HGF hepatocyte growth factor
- the left end is the N-terminus (amino terminus) and the right end is the C-terminus (carboxyl terminus) in accordance with the convention of peptide labeling.
- Tanpagu protein and receptor used in the present invention C-terminal, carboxyl group (-C00H), Karupokishi rate (- C00-), Ami de (-C0NH 2) or ester (- C00R) but it may also be either .
- R in the ester is, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl and the like.
- Alkyl group for example, cyclopentyl, C 3 _ 8 cycloalkyl group such as cyclohexyl, for example, phenylene. Le, alpha-naphthyl and the like.
- 6 _ 12 Ariru group, e.g., benzyl, phenylene Lou C ⁇ alkyl group or alpha, such as phenethyl - such as naphthylmethyl alpha - Nafuchiru C, etc.
- _ 9 alkyl group C 7 _ 14 aralkyl group, piperoyloxymethyl group and the like are used.
- the protein used in the present invention has a lipoxyl group (or lipoxylate) other than the C-terminus
- the protein in which the lipoxyl group is amidated or esterified is also included in the protein used in the present invention. included.
- the ester in this case for example, the above-mentioned C-terminal ester and the like are used.
- an amino group at the N-terminal amino acid residue (eg, a methionine residue) has a protecting group (for example, an acyl group such as a Cw alkanol such as a formyl group or an acetyl group).
- a protecting group for example, an acyl group such as a Cw alkanol such as a formyl group or an acetyl group.
- N-terminal glutamine residue generated by cleavage in vivo, pyroglutamic acid-substituted, substituent on the side chain of amino acid in the molecule eg, -0H, -SH, amino group , those imidazole group, I Ndoru group, etc. Guanijino group
- a suitable protecting group e.g., formyl group, etc.
- c Ashiru group such as c M Al force Noiru group such Asechi Le group
- a complex protein such as a so-called glycoprotein to which a sperm chain is bound.
- the partial peptide of the protein or the receptor used in the present invention is the partial peptide of the protein or the receptor used in the present invention described above, and is preferably the same as that of the present invention. Any one may be used as long as it has the same properties as the protein or receptor used.
- Peptides having 100 or more amino acid sequences are used.
- the partial peptide has one or two or more amino acids in its amino acid sequence (preferably about 1 to 20, more preferably about 1 to 10, and still more preferably about 1 to 5). Of amino acids, or 1 or 2 or more (preferably about 1 to 20, more preferably about 1 to 10, and still more preferably about 1 to 5) An amino acid is added, or 1 or 2 or more amino acids are added to the amino acid sequence (preferably, about 1 to 20; more preferably, about 1 to 10; Preferably, a number (1 to 5) of amino acids are inserted, or 1 or 2 or more (preferably about 1 to 20, more preferably about 1 to 10) in the amino acid sequence. (Preferably several, more preferably about 1 to 5) amino acids may be substituted with other amino acids.
- the partial peptide used in the present invention C-terminal carboxyl group (- C00H), carboxylate (- C00-), amide (_C0NH 2) or ester - may be either (C00R).
- the partial peptide used in the present invention includes those having a carboxyl group (or carboxylate) in addition to the C-terminal, N-terminal amino acid residues ( E.g., methionine residue) whose amino group is protected by a protecting group, glutamine residue generated by cleavage of N-terminal in vivo, pyroglutamic acid residue, substitution of side chain of amino acid in molecule Also included are those in which the group is protected by an appropriate protecting group, and those in which a sugar chain is bonded, such as a complex peptide such as a so-called glycopeptide.
- a carboxyl group or carboxylate
- the partial peptide used in the present invention can also be used as an antigen for producing an antibody.
- salts with physiologically acceptable acids eg, inorganic acids, organic acids
- bases eg, alkali metal salts
- physiologically acceptable acid addition salts include salts with inorganic acids (eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid) or organic acids (eg, acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid) Acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid) and the like.
- inorganic acids eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid
- organic acids eg, acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid
- Acid tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesul
- the protein or receptor used in the present invention or a partial peptide thereof or a salt thereof can be produced from the above-mentioned human or warm-blooded animal cell or tissue by a protein purification method known per se, or a protein encoding a protein. It can also be produced by culturing a transformant containing the DNA of the present invention. Also, it can be produced according to the peptide synthesis method described later.
- the cells When produced from human or mammalian tissues or cells, Alternatively, the cells can be homogenized, extracted with an acid or the like, and the extract can be purified and isolated by combining chromatography such as reverse phase chromatography and ion exchange chromatography.
- chromatography such as reverse phase chromatography and ion exchange chromatography.
- a commercially available resin for protein synthesis can usually be used.
- resins include, for example, chloromethyl resin, hydroxymethyl resin, benzhydrylamine resin, aminomethyl resin, 4-benzyloxybenzyl alcohol resin, 4-methylbenzhydrylamine resin, PAM resin, 4-Hydroxymethylmethylphenylacetamide methyl resin, polyacrylamide resin, 4- (2,, 4 'dimethylphenylhydroxymethyl) phenoxy resin, 4- (2', 4, dimethylmethoxyphenol) F moc aminoethynole) phenoxy resin and the like.
- an amino acid having an amino group and a side chain functional group appropriately protected is condensed on the resin in accordance with the sequence of the target protein according to various condensation methods known per se.
- the protein or partial peptide is cleaved from the resin, and at the same time, various protecting groups are removed.
- an intramolecular disulfide bond formation reaction is performed in a highly diluted solution to obtain the target protein or partial peptide or their amide. Get the body.
- the protected amino acid may be added directly to the resin along with a racemization inhibitor (eg, HOBt, HOOBt) or may be pre-protected as a symmetrical acid anhydride or HOBt ester or HOOBt ester.
- the amino acid can be added to the resin after activation.
- the solvent used for activating the protected amino acid or condensing with the resin can be appropriately selected from solvents known to be usable for the protein condensation reaction.
- acid amides such as N, N-dimethylformamide, N, N-dimethylacetamide, N-methylvirolidone, and halogenated carbons such as methylene chloride and chloroform.
- Hydrogens alcohols such as trifluoroethanol, sulfoxides such as dimethyl sulfoxide, ethers such as pyridine, dioxane, and tetrahydrofuran; nitriles such as acetonitrile and propionitrile; esters such as methyl acetate and ethyl acetate.
- the reaction temperature is appropriately selected from a range known to be usable for a protein bond formation reaction, and is usually appropriately selected from a range of about ⁇ 20 to 50 ° C.
- the activated amino acid derivative is usually used in a 1.5 to 4-fold excess.
- Examples of the protecting group for the amino group of the starting material include Z, Boc, t-pentyloxycarpo-enole, isopollinoleoxycarbonyl, 4-methoxybenzyloxy-canoleponyl, C11Z, Br-Z, a Damantyloxycarbonyl, trifluoroacetinole, phthaloynole, honole 5: nore, 2-nitropheninoles norefeinole, dipheninole phosphinochioil, Fmoc and the like are used.
- the carboxyl group may be, for example, a linear, branched or cyclic alkyl esterified (eg, methyl, ethyl, propynole, ptinole, t-butyl, cyclopentynole, cyclohexynole, cycloheptyl, cyclooctyl, 2-adamantyl) Alkyl esterification), aralkyl esterification (eg, benzyl ester, 4-nitrobenzinolestenol, 4-methoxybenzinolestenol, 4-monobenzinolester, benzhydryl esterification), hues It can be protected by nasyl esterification, benzyloxycarbonyl hydrazide, t-butoxycarbonyl hydrazide, trityl hydrazide, or the like.
- a linear, branched or cyclic alkyl esterified eg,
- the hydroxyl group of serine can be protected, for example, by esterification or etherification.
- Suitable groups for the esterification include, for example, lower (C ⁇ 6 ) alkanol groups such as acetyl group, aroyl groups such as benzoyl group, and groups derived from carbonic acid such as benzyloxycarbonyl group and ethoxycarbonyl group.
- a group suitable for etherification include a benzyl group, a tetrahydrovinylinole group, and a t-butyl group.
- the protecting group of the phenolic hydroxyl group of tyrosine for example, B z 1, C 1 2 - B zl, 2- two Torobenjiru, B r- Z, such as t one-butyl is used.
- Examples of the protecting group for imidazole of histidine include Tos, 4-methoxy-1,2,3,6_trimethinolebenzenesnorefoninole, DNP, benzizoleoxymethinole, Bum, Boc, Trt, Fmoc or the like is used.
- activated carboxyl groups in the raw materials include, for example, corresponding acid anhydrides, azides, active esters [alcohols (eg, pentachlorophenol, 2,4,5-trichlorophenol, 2,4-dinitrophenol); Nore, cyanometinole alcohol, paranitrophenol, HONB, N-hydroxysuccinimide, N-hydroxyphthalimid, ester with HOB t).
- active esters eg, pentachlorophenol, 2,4,5-trichlorophenol, 2,4-dinitrophenol
- Nore cyanometinole alcohol, paranitrophenol, HONB, N-hydroxysuccinimide, N-hydroxyphthalimid, ester with HOB t.
- the activated amino group of the raw material for example, a corresponding phosphoric acid amide is used.
- Methods for removing (eliminating) protecting groups include, for example, catalytic reduction in a hydrogen stream in the presence of a catalyst such as Pd-black or Pd-carbon, hydrogen anhydride, methanesulfonic acid, and the like.
- a catalyst such as Pd-black or Pd-carbon, hydrogen anhydride, methanesulfonic acid, and the like.
- Acid treatment with trifluoromethanesulfonic acid, trifluoroacetic acid or a mixture thereof, base treatment with diisopropylethylamine, triethylamine, piperidine, piperazine, etc., or with sodium in liquid ammonia Reduction is also used.
- the elimination reaction by the above-mentioned acid treatment is generally carried out at a temperature of about 120 ° C to 40 ° C.
- a desired peptide (protein) chain is added to the amino group side.
- the desired protein can be obtained in the same manner as the amide of protein or peptide. It is possible to obtain an ester of quality or a peptide.
- the partial peptide or a salt thereof used in the present invention can be produced according to a peptide synthesis method known per se, or by cleaving the protein used in the present invention with an appropriate peptidase.
- a method for synthesizing a peptide for example, any of a solid phase synthesis method and a liquid phase synthesis method may be used. That is, a partial peptide or an amino acid that can constitute the partial peptide used in the present invention is condensed with the remaining portion, and when the product has a protecting group, the protecting group is eliminated to give the desired peptide. Can be manufactured. Examples of the known condensation method and elimination of the protecting group include the methods described in the following (i) and (v).
- the polynucleotide encoding the protein used in the present invention may be any polynucleotide containing the above-described nucleotide sequence encoding the protein used in the present invention.
- it is DNA.
- the DNA include genomic DNA, genomic DNA library, the above-mentioned cell or tissue-derived cDNA, the above-mentioned cell or tissue-derived cDNA library, and synthetic DNA. Any of teriophage, plasmid, cosmid, phagemid and the like may be used.
- amplification can be carried out directly by Reverse Transcriptase Polymerase Chain Reaction (hereinafter abbreviated as RT-PCR method) using a total RNA or mRNA fraction prepared from the above-mentioned cell'tissue.
- RT-PCR method Reverse Transcriptase Polymerase Chain Reaction
- Examples of the DNA encoding the protein used in the present invention include:
- DNA containing the nucleotide sequence represented by SEQ ID NO: 5, or SEQ ID NO: 5 Encodes a protein having a nucleotide sequence that hybridizes under high stringent conditions with the nucleotide sequence represented by D NA,
- Examples of the DNA that can hybridize with the nucleotide sequence represented by SEQ ID NO: 2 under high stringent conditions include, for example, 95% or more, and preferably about 98 or more of the nucleotide sequence represented by SEQ ID NO: 2.
- a DNA containing a base sequence having a homology of about 99% or more is used.
- Examples of a DNA that can hybridize with the nucleotide sequence represented by SEQ ID NO: 5 under high stringent conditions include, for example, a DNA having 99.9% or more homology with the nucleotide sequence represented by SEQ ID NO: 5 DNA containing a base sequence is used.
- Examples of the DNA that can hybridize with the base sequence represented by SEQ ID NO: 8 under high stringency conditions include, for example, a base having 99.9% or more homology with the base sequence represented by SEQ ID NO: 8 DNA containing a sequence is used.
- DNAs that can hybridize with the nucleotide sequence represented by SEQ ID NO: 11 under high stringent conditions include, for example, 99.9% or more of the nucleotide sequence represented by SEQ ID NO: 11.
- DNA containing a homologous nucleotide sequence or the like is used.
- Hybridization can be performed according to a method known per se or a method analogous thereto, for example, a method described in Molecular Cloning 2nd (J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989). When a commercially available library is used, it can be performed according to the method described in the attached instruction manual. . More preferably, it can be performed under high stringent conditions.
- High stringency conditions include, for example, a sodium concentration of about 19-4 OmM, preferably about 19-20 mM, and a temperature of about 50-70 ° C, preferably about 60-70 ° C.
- the conditions at 65 ° C are shown. In particular, the case where the sodium concentration is about 19 mM and the temperature is about 65 is most preferable.
- the DNA encoding the protein containing the amino acid sequence represented by SEQ ID NO: 1 includes a DNA containing the nucleotide sequence represented by SEQ ID NO: 2 or a sequence DNA containing the nucleotide sequence represented by SEQ ID NO: 3 or the like;
- the DNA encoding the protein containing the amino acid sequence represented by SEQ ID NO: 4 includes the nucleotide represented by SEQ ID NO: 5
- the DNA containing the sequence or the DNA containing the base sequence represented by SEQ ID NO: 6 is (iii) a DNA encoding the protein containing the amino acid sequence represented by SEQ ID NO: 7; DNA having the nucleotide sequence represented by SEQ ID NO: 8 or DNA having the nucleotide sequence represented by SEQ ID NO: 9; and (iv) having the amino acid sequence represented by SEQ ID NO: 10 SEQ ID NO: D N A or SEQ ID NO containing the base sequence represented by 1: D N A, etc. is used which contains the base sequence represented
- the polynucleotide (eg, DNA) encoding the partial peptide used in the present invention may be any polynucleotide containing the above-described nucleotide sequence encoding the partial peptide used in the present invention. Further, any of a genomic DNA, a genomic DNA library, the above-described cell DNA-derived cDNA, the above-described cell DNA-derived library, and synthetic DNA may be used.
- Examples of the DNA encoding the partial peptide used in the present invention include, for example, a DNA containing the base sequence represented by SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, or SEQ ID NO: 11.
- a DNA containing a part of a DNA encoding a protein having substantially the same activity as the protein of the present invention is used.
- DNAs capable of hybridizing with the nucleotide sequence represented by SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8 or SEQ ID NO: 11 have the same significance as described above.
- the polynucleotide encoding the receptor used in the present invention may be any polynucleotide containing the above-described nucleotide sequence encoding the receptor used in the present invention.
- it is DNA.
- the DNA may be any of a genomic DNA, a genomic DNA library, the above-described cell and tissue-derived cDNA, the above-described cell and tissue-derived cDNA library, and a synthetic DNA.
- the vector used for the library may be any of pacteriophage, plasmid, cosmid, phagemid and the like.
- amplification can be performed directly by Reverse Transcriptase Polymerase Chain Reaction (hereinafter abbreviated as RT-PCR method) using a total RNA or mRNA fraction prepared from the above-described cell tissue.
- Examples of the DNA encoding the receptor used in the present invention include, for example, a DNA containing the nucleotide sequence represented by SEQ ID NO: 35, or a DNA comprising the nucleotide sequence represented by SEQ ID NO: 35 and high stringency. And DNA encoding a protein having a nucleotide sequence that hybridizes under unique conditions and having substantially the same properties as a protein having the amino acid sequence represented by SEQ ID NO: 26.
- Examples of the DNA that can hybridize with the base sequence represented by SEQ ID NO: 35 under high stringent conditions include, for example, about 50% or more, preferably DNA containing a nucleotide sequence having a homology of about 60% or more, preferably about 70% or more, preferably about 80% or more, preferably about 90% or more, and preferably about 95% or more. Is used.
- Hybridization can be carried out according to a method known per se or a method analogous thereto, for example, the method described in Molecular Cloning 2nd (J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989). When a commercially available library is used, it can be performed according to the method described in the attached instruction manual. . More preferably, it can be performed under high stringent conditions.
- High stringent conditions include, for example, a sodium concentration of about 19-4 OmM, preferably about 19-20 mM, and a temperature of about 50-70 ° C, preferably about 60 ° C. The conditions at ⁇ 65 ° C are shown. In particular, the case where the sodium concentration is about 19 mM and the temperature is about 65 is most preferable.
- DNA encoding the protein containing the amino acid sequence represented by SEQ ID NO: 26 a DNA containing the base sequence represented by SEQ ID NO: 35 or the like is used.
- the DNA base sequence can be converted using PCR, a known kit, for example, Mutan TM -super Express Km (Takara Bio Inc.), Mutan TM -K (Takara Bio Inc.), and the like.
- the method can be performed according to a method known per se, such as the method, the gapped duplex method, the Kunkel method, or a method analogous thereto.
- the DNA encoding the cloned protein can be used as it is depending on the purpose, or can be used by digesting with a restriction enzyme or adding a linker if desired.
- the DNA may have ATG on its 5, terminal side as a translation initiation codon, and may have TAA, TGA or TAG on its 3, terminal side as a translation stop codon. These translation start codons and translation stop codons are It can also be added using a adapter.
- Examples of the expression vector for the protein of the present invention include (a) cutting out a DNA fragment of interest from DNA encoding the protein of the present invention, and (mouth) connecting the DNA fragment downstream of a promoter in an appropriate expression vector. It can be manufactured by
- Examples of the vector include Escherichia coli-derived plasmid (eg, pBR322, pBR325, pUC12, pUC13), Bacillus subtilis-derived plasmid (eg, pUB110, pTP5, pC194), yeast-derived plasmid (Eg, pSH19, pSH15), pacteriophages such as ⁇ phage, animals such as retro-inoles, vacsuawinores, and baculovirus, etc., pAl-11, ⁇ 1, Rc / CMV, pRc / RSV, p cDNAI / Neo or the like is used.
- Escherichia coli-derived plasmid eg, pBR322, pBR325, pUC12, pUC13
- Bacillus subtilis-derived plasmid eg, pUB110, pTP5, pC194
- yeast-derived plasmid Eg
- the promoter used in the present invention may be any promoter as long as it is appropriate for the host used for gene expression.
- SRa promoter when animal cells are used as host, SRa promoter, SV40 promoter, LTR open motor, CMV promoter, HSV-TK promoter and the like can be mentioned.
- CMV cytomegalovirus
- SRa promoter an SRa promoter and the like.
- the host is Escherichia, tr ⁇ promoter, la. Promoter, recA promoter, ⁇ ⁇ promoter, lpp promoter, T7 promoter, etc.
- the host is Bacillus sp., SPOL promoter, SP02 promoter, penP promoter, etc.
- the host is yeast Preferred are PHO5 promoter, PGK promoter, GAP promoter, ADH promoter and the like.
- a polyhedrin promoter, a P10 promoter and the like are preferable.
- the expression vector may further include an enhancer, a splicing signal, a polyA addition signal, a selection marker, an SV40 replication origin (hereinafter sometimes abbreviated as SV40 ori), and the like, if desired.
- SV40 ori an SV40 replication origin
- the selection marker include dihydrofolate reductase (hereinafter sometimes abbreviated as dh fr) gene [methotrexate (MTX) resistance], ampicillin phosphorus resistant gene (hereinafter sometimes abbreviated as Amp r), neomycin Resistant Gene (hereinafter sometimes abbreviated as Neo r , G4 18 resistance).
- dhfr gene when used as a selection marker using Chinese hamster cells deficient in the dhfr gene, the target gene can be selected using a thymidine-free medium.
- a signal sequence suitable for the host is added to the N-terminal side of the protein of the present invention.
- the host is a bacterium belonging to the genus Escherichia, a PhoA ′ signal sequence, an OmpA signal sequence, etc.
- the host should include a signal sequence, a signal sequence, a subtilisin signal sequence, etc.
- yeast MFa signal sequence, SUC2 signal sequence, etc.
- insulin signal sequence ⁇ -interferon 'signal sequence, antibody molecule' signal sequence, etc. Available for each.
- a transformant can be produced.
- Escherichia bacteria for example, Escherichia bacteria, Bacillus bacteria, yeast, insect cells, insects, animal cells, and the like are used.
- Escherichia examples include, for example, Escherichia coli K12 ⁇ DH1 [Proc. Natl. Acad. Sci. USA, 60, 160 (1968)], JMl03 [Nucleic Acids Research, 93 ⁇ 4309 (1981)], JA221 (Journal of Molecular Biology, 120, 517 (1978)), HB101 Cjournal of Molecular Biology, 41, 459 (1969), C60 0 [Genetics, 39, 440 (1954)].
- Bacillus subtilis examples include, for example, Bacillus subtilis (MI) 114 [Gene, 24, 255 (1983)], 207-21 [Journal of Biochemistry, 95, 87 (1984)] are used.
- yeast examples include, for example, Saccharomyces cerevisiae AH22, AH22R-, NA87-11A, DKD-5D, 20B-12, Schizosaccharomyces pombe NC YC 1913, NCYC 203, Pichia pastoris KM71 and the like are used.
- insect cells for example, if the virus is Ac NPV, the larvae of the night rob moth Spodoptera frugiperda cell (Sf cell), MG1 cell from Trichoplusia ni midgut, High Five TM cell from Trichoplusia ni egg, Mamestra brassicae-derived cell or Estigmena acrea-derived cell .
- Sf cell a silkworm-derived cell line (Bonibyxmori N cell; BmN cell) or the like is used.
- Sf cells for example, Sf9 cells (ATCCCRL1711), Sf21 cells (above, Vaughn, JL et al., In Vivo, 13, 213-217, (1977)) and the like are used.
- insects for example, silkworm larvae are used [Maeda et al., Nature, Vol. 315, 592 (1985)].
- animal cells examples include monkey cell COS-7, Vero, Chinese hamster cell CHO (hereinafter abbreviated as CHO cell), and dhfr gene-deficient hamster cell CHO cell (hereinafter abbreviated as CHO (dhfr-) cell).
- CHO cell Chinese hamster cell CHO
- dhfr- dhfr gene-deficient hamster cell CHO cell
- Mouse L cells mouse AtT-20, mouse myeloma cells, mouse ATDC5 cells, rat GH3, human FL cells, and the like.
- Transformation of the genus Escherichia can be performed, for example, according to the method described in Pro Natl. Acad. Sci. USA, 69, 2110 (1972) or Gene, 17, 107 (1982).
- Transformation of Bacillus spp. Can be performed, for example, according to the method described in Molecular & General Genetics, Vol. 168, 111 (1979).
- Insect cells or insects can be transformed, for example, according to the method described in Bio / Technology, 6, 47-55 (1988).
- a transformant transformed with the expression vector containing the DNA encoding the protein can be obtained.
- a liquid medium is suitable as a medium for culturing, and a carbon source necessary for the growth of the transformant is contained therein.
- the carbon source include glucose, dextrin, soluble starch, and sucrose.
- the nitrogen source include ammonium salts, nitrates, cone chip liquor, peptone, casein, meat extract, soybean meal, and potato.
- inorganic or organic substances and inorganic substances such as an extract include calcium chloride, sodium dihydrogen phosphate, magnesium chloride and the like. Also, yeast extract, vitamins and growth promoting factors may be added.
- the pH of the medium is preferably about 5 to 8 9
- an M9 medium containing glucose and casamino acid can be used as a medium for cultivating a bacterium belonging to the genus Escherichia.
- an M9 medium containing glucose and casamino acid can be used as a medium for cultivating a bacterium belonging to the genus Escherichia.
- a drug such as 3-indolylataryl acid can be added to make the promoter work efficiently if necessary.
- the cultivation is usually carried out at about 15 to 43 ° C for about 3 to 24 hours, and if necessary, aeration and stirring can be applied.
- the cultivation is usually carried out at about 30 to 40 ° C for about 6 to 24 hours, and if necessary, aeration and stirring may be applied.
- the culture medium When culturing a transformant in which the host is yeast, the culture medium may be, for example, a Parkholder (Burkholder) minimal medium [Proc. Natl. Acad. Sci, USA, 77, 4505 (1980)] or 0.5. % Casamino acid [Proc. Natl. Acad. Sci. USA, 81, 5330 (1984)].
- the pH of the medium is adjusted to about 5-8. Cultivation is usually performed at about 20 ° C to 35 ° C for about 24 to 72 hours, and aeration and agitation can be used as necessary.
- Culturing transformants whose host is insect cells or insects.
- a supplement such as 10% serum serum immobilized in Grace's Insect Medium (Nature, 195, 788 (1962)) are appropriately added.
- the pH of the medium is preferably adjusted to about 6.2 to 6.4. Culture is usually performed at about 27 ° C for about 3 to 5 days, and aeration and agitation are added as necessary.
- the culture medium may be, for example, a MEM medium containing about 5 to 20% fetal bovine serum [Science, 122, 501 (1952)], DMEM Medium [Virology, 8 volumes, 396 (1959)], RPMI 1640 medium [The Journal of the American Medical Association, 199 volumes, 519 (1967), 1 9 9 medium [Proceeding of the Society for the Biological Medicine, 73, 1 (1950)], etc. H is preferably about 6 to 8. Culture is usually carried out at about 30 to 40 ° C for about 15 to 60 hours, and if necessary. Add aeration and agitation.
- the protein of the present invention can be produced in the cells, in the cell membrane, or outside the cells of the transformant.
- the protein of the present invention can be separated and purified from the culture by, for example, the following method.
- the cells or cells When extracting the protein of the present invention from cultured cells or cells, after culturing, the cells or cells are collected by a known method, suspended in an appropriate buffer, and subjected to sonication, lysozyme and / or freeze-thawing. After the cells or cells are destroyed by, for example, a method of obtaining a crude protein extract by centrifugation or filtration is used as appropriate.
- the buffer may contain a protein denaturant such as urea or guanidine hydrochloride, or a surfactant such as Triton X-100 TM.
- the protein contained in the culture supernatant or extract obtained in this manner can be purified by appropriately combining known separation and purification methods.
- known separation and purification methods include methods using solubility such as salting out and solvent precipitation, dialysis, ultrafiltration, gel filtration, and SDS-polyacrylamide gel electrophoresis.
- a method utilizing a difference in hydrophobicity, a method utilizing a difference in isoelectric point such as isoelectric focusing, and the like are used.
- the salt can be converted to a salt by a method analogous thereto, and conversely, when a salt is obtained, it can be converted to a free form or another salt by a method known per se or a method analogous thereto.
- the protein produced by the recombinant can be arbitrarily modified or the polypeptide can be partially removed by the action of an appropriate protein-modifying enzyme before or after purification.
- an appropriate protein-modifying enzyme for example, trypsin, chymotrypsin, anoregininole endopeptidase, protein kinase, dalicosidase and the like are used.
- the presence of the protein of the present invention thus produced can be measured by, for example, enzymatic immunoassay western blotting using a specific antibody.
- a salt thereof the protein used in the present invention
- a protein containing an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO: 26 or a partial peptide thereof or a salt thereof this Examples of the substance that inhibits the binding to the receptor used in the present invention include substances that inhibit the binding between the protein used in the present invention and the receptor used in the present invention (eg, antibodies, peptides, proteins, non-peptides).
- Antibody specifically reacting with the protein used in the present invention antibody specifically reacting with the receptor used in the present invention, bispecific reacting specifically with the protein used in the present invention and the receptor used in the present invention
- Antibody that inhibits the activity of the receptor used in the present invention eg, the protein binding activity used in the present invention, the activity of phosphorylation
- the activity of the protein used in the present invention eg, the present invention
- Antibodies that inhibit the receptor binding activity used, the phosphorylation-inducing / promoting activity of the receptor used in the present invention (hereinafter, these may be collectively referred to as the antibodies of the present invention), and the like.
- the “substance which inhibits the activity of the protein used in the present invention” includes the activity of the protein used in the present invention (eg, the receptor binding activity used in the present invention, Substances that inhibit the receptor phosphorylation induction / promoting activity used in the invention (eg, antibodies, peptides, proteins, non-peptide compounds, synthetic compounds, fermentation products, cell extracts, plant extracts, animal tissue extractions) Liquid) can be used, and examples thereof include the antibody of the present invention.
- the substance that inhibits the activity of the receptor used in the present invention eg, the protein binding activity, phosphorylation activity and the like used in the present invention
- any antibody, peptide, protein, non-peptide compound, synthetic compound, fermentation product, cell extract, plant extract, animal tissue extract, etc. may be used.
- the antibody of the present invention may be either a polyclonal antibody or a monoclonal antibody.
- the antibody of the present invention is preferably an antibody (neutralizing activity antibody) having an activity of neutralizing the stimulation of cancer cell growth caused by the binding of the protein used in the present invention to the receptor used in the present invention.
- it is an antibody that inhibits the activity (preferably, the activity of being phosphorylated) of the receptor used in the present invention. More preferably, it is a monoclonal antibody.
- antigen used for preparing the antibody of the present invention examples include amino acids represented by SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7 or SEQ ID NO: 10, or SEQ ID NO: 26. Any peptide such as a protein containing an acid sequence or a partial peptide or a salt thereof (synthetic) peptide having one or two or more antigenic determinants can be used. It may be referred to as the antigen of the present invention).
- the above protein or its partial peptide or its salt can be produced according to the following Reference Examples and known methods. Further, (a) it is known from mammalian tissues or cells such as human, monkey, rat, mouse and the like. Using the method described in (B) chemically synthesized by a known peptide synthesis method using peptide synthesizer, etc., (c) SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7 or SEQ ID NO: 1 Alternatively, it can be produced by culturing a transformant containing a DNA encoding the polypeptide containing the amino acid sequence represented by SEQ ID NO: 26 or a salt thereof.
- the tissue or cells are homogenized, and the crude fraction (eg, membrane fraction, soluble fraction) is left as it is. It can also be used as an antigen.
- extraction is performed with an acid, surfactant, alcohol, or the like, and the extract is subjected to close chromatography such as salting out, dialysis, gel filtration, reverse phase chromatography, ion exchange chromatography, and affinity chromatography. Purification and isolation can also be performed by combining them.
- the synthetic peptide has the same structure as the antigen of the present invention purified from a natural material using, for example, the method (a) described above.
- SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7 or SEQ ID NO: 10 or any amino acid sequence represented by SEQ ID NO: 26 consisting of 3 or more, preferably 6 or more amino acids Peptides containing one or more amino acid sequences identical to the amino acid sequence at the position (1) are used.
- the DNA can be prepared by a known closing method (for example, a method described in Molecular Cloning (2nd ed .; J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989)). ].
- the cloning method includes: (1) a protein containing the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7 or SEQ ID NO: 10, or SEQ ID NO: 26, or a protein thereof; SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7 or SEQ ID NO: 10, or SEQ ID NO: 1 by hybridization using a DNA probe or DNA primer designed based on the amino acid sequence of the salt from the cDNA library A method for obtaining a transformant containing DNA encoding the protein containing the amino acid sequence represented by 26 or a salt thereof, or (2) SEQ ID NO: 1, SEQ ID NO: No .: 4, SEQ ID NO: 7 or SEQ ID NO: 10, or a DNA primer designed based on the amino acid sequence of a polypeptide containing an amino acid sequence represented by SEQ ID NO: 26 or a salt thereof, Contains DNA encoding the protein containing the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7
- Mammalian cells themselves that express the protein or receptor used in the present invention can also be used directly as the antigen of the present invention.
- a mammalian cell a natural cell as described in the above (a), a cell transformed by the method as described in the above (c), and the like can be used.
- the host used for the transformation may be any cell collected from human, sanore, rat, mouse, hamster, etc. SP2 / 0, P3U1, B16 or P388 are preferably used.
- Natural or transformed mammalian cells expressing the protein or receptor used in the present invention may be suspended in a medium (eg, RPMI1640) or a buffer (eg, Hanks' Balanced Salt Solution) used for tissue culture.
- a medium eg, RPMI1640
- a buffer eg, Hanks' Balanced Salt Solution
- the immunized animal can be injected in a turbid state.
- any method can be used as long as it can promote antibody production, and intravenous injection, intraperitoneal injection, intramuscular injection, or subcutaneous injection is preferably used.
- the peptide as the antigen of the present invention may be prepared by (1) a known peptide synthesis method, or (2) SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7 or SEQ ID NO: 10, or SEQ ID NO: 2. It can also be produced by cleaving a protein containing the amino acid sequence represented by 6 with an appropriate peptidase.
- the target peptide can be produced by condensing a partial peptide or amino acid capable of constituting the peptide with the remaining portion and, when the product has a protecting group, removing the protecting group.
- Examples of the known condensation method and elimination of the protecting group include the methods described below.
- the peptide can be purified and isolated by a combination of ordinary purification methods such as solvent extraction, distillation, column chromatography, liquid chromatography, and recrystallization.
- the peptide obtained by the above method is a free form, it can be converted to an appropriate salt by a known method, and conversely, when the peptide is obtained by a salt, it is converted to a free form by a known method can do.
- a commercially available resin for peptide synthesis suitable for amide formation can be used.
- resins include chloromethyl resin, hydroxymethyl resin, benzhydrylamine resin, aminomethyl resin, 4-benzyloxybenzyl alcohol resin, 4-methylbenzhydrylamine resin, PAM resin, Hydroxymethylmethylphenylacetamidomethyl resin, polyacrylamide resin, 4- (2,4, -dimethoxyphenoxyhydroxymethyl) phenoxy resin, 4_ (2,, 4, -dimethoxyphenyl) F moc aminoethyl) phenoxy resin.
- an amino acid having an appropriately protected 1,2, -amino group and a side chain functional group is condensed on the resin according to the sequence of the target peptide according to various known condensation methods.
- the peptide is cleaved from the resin and at the same time, various protecting groups are removed to obtain the desired peptide.
- a partially protected peptide may be taken out using a chlorotrityl resin, an oxime resin, a 4-hydroxybenzoic acid-based resin, or the like, and the protecting group may be removed by a conventional method to obtain a desired peptide.
- carbodiimides are particularly preferable.
- carpoimides include DCC, N, N, 1-diisopropyl carpoimide, N-ethyl-N '-(3-dimethylaminoprolyl) carpoimide, and the like.
- Activation by these methods involves the direct addition of a protected amino acid to the resin together with a racemization inhibitor (eg, HOBt, HOOBt, etc.) or a symmetric acid anhydride or HOBt ester or HOOBt.
- the amino acid protected as a t-ester can be added to the resin after activation.
- the solvent used for activating the acid or condensing with the resin can be appropriately selected from solvents known to be usable for the peptide condensation reaction.
- acid amides such as N, N-dimethylformamide, N, N-dimethylacetamide, and N-methylpyrrolidone
- halogenated hydrocarbons such as dimethylene chloride and chloroform
- Anoreconores, snorreoxides such as dimethinoresnorolefoxide, tertiary amines such as pyridine, ethers such as dioxane and tetrahydrofuran, nitriles such as acetonitrile and propionitrile, methyl acetate, acetic acid Esters such as ethyl or an appropriate mixture thereof are used.
- the reaction temperature is appropriately selected from a range known to be usable for the peptide bond formation reaction, and is usually appropriately selected from a range of about 120 ° C to about 50 ° C.
- the activated amino acid derivative is usually used in about 1.5 to about 4-fold excess.
- Examples of the protecting group for the amino group of the starting amino acid include Z, Boc, tertiary pentynoleoxycanoleponinole, isobonoleenoleoxycanoleponinole, and 4-methoxybenzyloxycarbonyl / , C11-Z, Br_Z, adamantinoleoxycarboxyl, trifluoroacetyl, phthaloyl, honolemil, 2-ditrophenylsnolephenyl, diphenylphosphinochioyl, Fmoc, etc. It is.
- the hydroxyl groups of serine and threonine can be protected, for example, by esterification or etherification.
- Suitable groups for this esterification include lower (Cw) alkanol groups such as acetyl group, aroyl groups such as benzoyl group, Examples thereof include groups derived from carbonic acid such as a ziroxycarbonyl group and an ethoxycarbonyl group.
- groups suitable for ethereal dani include, for example, a benzyl group, a tetrahydrovinylinole group, and a t-butyl / le group.
- phenolic hydroxyl-protecting group for tyrosine examples include Bz1, C1-Bz1,2-nitrobenzyl, Br-Z, t-butyl and the like.
- Examples of the protecting group for imidazole of histidine include Tos, 4-methoxy2,3,6-trimethylbenzenesulfur, DNP, Bom, Bum, Boc, Trt, and Fmoc.
- Activated carboxyl groups of the raw materials include, for example, corresponding acid anhydrides, azides, and activated esters [alcohols (eg, pentachlorophenol, 2,4,5-trichlorophenol, 2,4-dinitrophenol, cyanomethiol) Norenoconore, paranitrophenolone, HONB, N-hydroxysuccinimide, N-hydroxyphthalimid, ester with HOB t)].
- Activated amino groups of the raw material include, for example, the corresponding phosphoric acid amide.
- Methods for removing (eliminating) protecting groups include catalytic reduction in the presence of a catalyst such as Pd-black or Pd-carbon in a stream of hydrogen, hydrogen fluoride anhydride, methanesulfonic acid, Acid treatment with trifluoromethanesulfonic acid, trifluoroacetic acid or a mixture thereof, base treatment with diisopropylethylamine, triethylamine, piperidine, piperazine, etc., or with sodium in liquid ammonia Reduction is also included.
- the elimination reaction by the above-mentioned acid treatment is generally carried out at a temperature of from 20 ° C to 40 ° C. 4.
- an amide form of the peptide first, after amidating the ⁇ - functional propyloxyl group of the carboxyl terminal amino acid, the peptide chain is extended to a desired chain length on the amino group side, and then the peptide is added.
- the peptide was prepared by removing only the protecting group of the ⁇ ⁇ ⁇ -terminal monoamino group of the chain and the peptide (or amino acid) by removing only the protecting group of the C-terminal lipoxyl group. Condensation in such a mixed solvent. Details of the condensation reaction are the same as described above.
- the ⁇ -carboxyl group of the amino acid at the terminal end of the lipoxy group is condensed with a desired alcohol to form an amino acid ester, and then the ester of the desired peptide is obtained in the same manner as the amide of the peptide Can be.
- the antigen of the present invention can also be used to directly immunize an insoluble one.
- a complex obtained by binding or adsorbing the antigen of the present invention to a suitable carrier may be immunized.
- the mixing ratio of the carrier (carrier) and the antigen (hapten) of the present invention is determined by what ratio and what ratio as long as the antibody can be efficiently produced with respect to the antigen of the present invention bound or adsorbed to the carrier.
- a natural or synthetic polymer carrier commonly used in the production of antibodies to hapten antigens is bound or adsorbed at a weight ratio of 0.1 to 100 with respect to 1 hapten. Things can be used.
- Natural polymer carriers include, for example, serum albumin of mammals such as sea lions, egrets, humans, etc., and thyroglobulin of mammals such as sea lions, egrets, etc. Hemoglobin, keyhole limpet, and mococyanin are used.
- Examples of the synthetic polymer carrier include polymers such as polyamino acids, polystyrenes, polyacryls, polybutyls, and polypropylenes, and various types of latetus such as copolymers. Also, various condensing agents can be used for force coupling between the hapten and the carrier.
- diazonium compounds such as bisdiazobenzidine that crosslink tyrosine, histidine, and tryptophan; dialdehyde compounds such as dartal aldehyde that crosslink amino groups; diisocyanate compounds such as toluene-1,2,4-diisocyanate; and crosslinks between thiol groups
- dimaleimide compound such as N, N, 1-phenylenedimaleimide, a maleimide active ester conjugate which crosslinks an amino group and a thiol group, a carpoimide compound which crosslinks an amino group and a carboxyl group, etc. are conveniently used.
- an active ester reagent having a dithiopyridyl group on one amino group eg, N-succinimidyl 3- (2-pyridyldithio) propionate
- the thiol group can be introduced by post-reduction, and the maleimide group can be introduced into the other amino group with a maleimide active ester reagent, and then reacted with each other.
- the antigen of the present invention can be administered to a warm-blooded animal alone or together with a carrier or diluent to a site where antibody production is possible by an administration method such as intraperitoneal injection, intravenous injection, or subcutaneous injection. Is done. Complete Freund's adjuvant ⁇ incomplete Freund's adjuvant may be administered in order to enhance the antibody-producing ability upon administration. Administration is usually performed once every 2 to 6 weeks, for a total of about 2 to 10 times.
- Warm-blooded animals include, for example, rabbits, rabbits, dogs, monoremots, mice, rats, sheep, goats, and chickens. Mice are preferably used for monoclonal antibody production.
- a warm-blooded animal immunized with the antigen of the present invention for example, an individual having an antibody titer is selected from a mouse, and the spleen or lymph node is collected 2 to 5 days after the final immunization.
- the antibody-producing hybridoma of the present invention can be prepared by fusing the antibody-producing cells contained therein with myeloma cells.
- the antibody titer of the antibody of the present invention in serum can be measured, for example, by labeling the protein or receptor used in the present invention with a radioactive substance or an enzyme and reacting with the antiserum, and then measuring the activity of the labeling agent bound to the antibody. This is done by measuring.
- the fusion operation is performed by a known method, for example, the method of Koehler and Milstein [Nature, vol. 256, p. 495 (1975 W 200
- Examples of the fusion promoter include polyethylene glycol (PEG) and Sendai virus.
- PEG polyethylene glycol
- Examples of myeloma cells include NS-1, P3U1, SP2 / 0, AP-1, and the like, and P3U1 and the like are preferably used.
- the preferred ratio between the number of antibody-producing cells (spleen cells) and the number of bone marrow cells used is usually about 1: 1 to 20: 1, and PEG (preferably PEG1000 to PEG6000) is used at a concentration of about 10 to 80%.
- Cell fusion can be carried out efficiently by incubating the mixture and incubating usually at 20 to 40 ° C, preferably at 30 to 37 ° C, usually for 1 to 10 minutes.
- Various methods can be used for screening the antibody-producing hybridoma of the present invention.
- it is represented by SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7 or SEQ ID NO: 10, or SEQ ID NO: 26.
- a hybridoma culture supernatant was added to a solid phase (eg, a microplate) on which a protein containing an amino acid sequence or a salt thereof or a partial peptide thereof was directly or adsorbed together with a carrier, and then labeled with a radioactive substance, an enzyme, or the like.
- the polypeptide containing the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7 or SEQ ID NO: 10 or SEQ ID NO: 26 And a method for detecting the antibody of the present invention.
- Screening and breeding of the antibodies of the present invention can usually be performed in animal cell culture media supplemented with HAT (hypoxanthine, aminopterin, thymidine).
- HAT hyperxanthine, aminopterin, thymidine
- any medium can be used as long as it can grow a hybridoma.
- RPMI 1640 medium containing 1 to 20%, preferably 10 to 20% fetal bovine serum, and GIT medium containing 1 to 10% fetal bovine serum (Wako Pure Chemical Industries, Ltd. ))
- serum-free medium for hybridoma culture SFM-101, Nissui Pharmaceutical Co., Ltd.
- the cultivation temperature is usually 20 to 40 ° C, preferably about 37 ° C.
- the culture time is usually 5 days to 3 weeks, preferably 1 week to 2 weeks.
- the culture can be usually performed under 5% carbon dioxide.
- the separation and purification of the antibody of the present invention is the same as the separation and purification of ordinary polyclonal antibodies. Separation and purification of epiglobulin [eg, salting out, alcohol precipitation, isoelectric point precipitation, electrophoresis, adsorption / desorption with ion exchanger (eg, 'DEAE), ultracentrifugation, gel filtration, A specific purification method in which only the antibody is collected using an antigen-binding solid phase or an active adsorbent such as protein A or protein G, and the bond is dissociated to obtain an antibody.
- the antibody of the present invention can be produced by culturing the hybridoma cells in vivo or in vitro of a warm-blooded animal and collecting the antibody from the body fluid or culture.
- the bispecific monoclonal antibody that specifically reacts with the protein used in the present invention and the receptor used in the present invention can be produced according to a known method.
- the polyclonal antibody of the present invention can be produced according to a method known per se or a method analogous thereto. For example, an immune antigen itself or a complex thereof with a carrier protein is formed, and immunization is performed on a warm-blooded animal in the same manner as in the above-described method for producing a monoclonal antibody, and the antibody-containing substance of the present invention is collected from the immunized animal.
- the antibody can be produced by separating and purifying the antibody.
- the type of the carrier protein and the mixing ratio of the carrier protein and the hapten are determined by the antibody against the hapten immunized by crosslinking the carrier protein. If efficient, cross-linking can be performed at any ratio, for example, ⁇ serum albumin ⁇ ⁇ thyroglobulin, hemocyanin, etc. in a weight ratio of about 0 01-2 to hapten 1 0, preferably about 1-5 crosslinks A method is used.
- various condensing agents can be used for crosslinking the hapten and the carrier protein, and glutaraldehyde-carboimide, a maleimide active ester, an active ester reagent containing a thiol group or a dithioviridyl group, or the like is used.
- the condensation product is administered to a warm-blooded animal at a site where antibody production is possible, itself or together with a carrier or diluent.
- Complete Freund's adjuvant or incomplete Freund's adjuvant may be administered in order to enhance the antibody-producing ability upon administration. The administration is usually made once every about 2 to 6 weeks, for a total of about 3 to 10 times.
- the polyclonal antibody can be collected from the blood, ascites, etc., preferably from the blood, of the warm-blooded animal immunized by the above method.
- the polyclonal antibody titer in the antiserum can be measured, for example, in the same manner as the antibody titer of the hybridoma culture supernatant described in (2) above. Separation and purification of the polyclonal antibody can be performed according to the same method for separation and purification of immunoglobulin as in the separation and purification of the monoclonal antibody described above.
- Polynucleotide encoding the protein or receptor used in the present invention or a partial peptide thereof eg, DNA (hereinafter, in the description of antisense polynucleotide, when these DNAs are abbreviated as DNAs of the present invention
- the antisense polynucleotide having a base sequence complementary to or substantially complementary to the base sequence of)) or a part thereof includes a base sequence of the polynucleotide (eg, DNA) of the present invention.
- Any antisense polynucleotide may be used as long as it contains a captive or substantially complementary base sequence or a part thereof and has an action capable of suppressing the expression of the DNA.
- Sense DNA is preferred.
- the nucleotide sequence substantially complementary to the DNA of the present invention refers to, for example, the entire nucleotide sequence or a partial nucleotide sequence of the nucleotide sequence complementary to the DNA of the present invention (that is, the complementary strand of the DNA of the present invention).
- a nucleotide sequence having a homology of 70% or more, preferably about 80% or more, more preferably about 90% or more, and most preferably about 95% or more is exemplified.
- (a) in the case of an antisense polynucleotide directed to translation inhibition, of the entire base sequence of the complementary strand of the DNA of the present invention It is about 70% or more, preferably about 80% or more, more preferably about 90% or more, and most preferably about 95% or more, complementary to the complementary sequence of the base sequence of the coding portion (eg, the base sequence near the start codon).
- the antisense polynucleotide having a homology of at least% is (mouth) an antisense polynucleotide which directs RNA degradation by RNase H, it is possible to reduce the amount of antisense polynucleotide by the phase capture of the entire nucleotide sequence of the DNA of the present invention including introns. 70% or more, preferably about 80% or more, more preferably about 90% or more, most preferably an antisense polynucleotide having a homology of about 95% or more.
- SEQ ID NO: 2 SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, Column ID: 11, SEQ ID NO: 12, SEQ ID NO: 35 DNA base containing base sequence
- An antisense polynucleotide having a complementary or substantially complementary base sequence or a portion thereof in the sequence preferably, for example, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6 SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 12 or SEQ ID NO: 35 or a part thereof which is complementary to the nucleotide sequence of the DNA containing the nucleotide sequence represented by SEQ ID NO: 35
- an antisense polynucleotide having The antisense polynucleotide is usually composed of about 10 to 40 bases, preferably about 15 to 30 bases.
- the phosphate residues (phosphates) of each nucleotide constituting the antisense DNA are, for example, chemically modified phosphate residues such as phosphorothioate, methylphosphonate, and phosphorodithionate. May be substituted.
- the sugar (deoxylipose) of each nucleotide may be substituted with a chemically modified sugar structure such as 2′_0_methylation, and the base (pyrimidine, purine) may also be chemically modified.
- SEQ ID NO: 2 SEQ ID NO: 3, SEQ ID NO: 5, gfi column ID: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 12 or SEQ ID NO :
- SEQ ID NO: 3 SEQ ID NO: 5 gfi column ID: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 12 or SEQ ID NO :
- Such an antisense polynucleotide can hybridize with RNA of the protein gene of the present invention, and has the ability to inhibit the synthesis or function of the RNA or through the interaction with the protein-related RNA of the present invention.
- the expression of the protein gene of the present invention can be regulated and controlled.
- Polynucleotides complementary to the selected sequence of the protein-related RNA of the present invention, and polynucleotides capable of specifically hybridizing with the protein-associated RNA of the present invention are in vivo or in vitro. It is useful for regulating and controlling the expression of the protein gene of the present invention, and is also useful for treating or diagnosing diseases and the like.
- corresponding means having homology or being complementary to a specific sequence of nucleotides, base sequences or nucleic acids including genes.
- the "correspondence" between a nucleotide, nucleotide sequence or nucleic acid and a protein usually refers to the amino acids of the (directed) protein derived from the nucleotide (nucleic acid) sequence or its complement.
- the end parindromic region or the three end hairpin loop can be selected as a preferred target region, but any region within a protein gene can be selected as a target.
- any region within a protein gene can be selected as a target.
- the target nucleic acid and a polynucleotide complementary to at least a part of the target region if the target nucleic acid can hybridize with the target region, the target nucleic acid is included in the polynucleotide of the target region. On the other hand, it can be said that it is “antisense”.
- Antisense polynucleotides include polynucleotides containing 2-dexoxy D-report, polynucleotides containing D-liposome, N-glycosides of purine or pyrimidine bases and other types of polynucleotides. , Other polymers having non-nucleotide backbones (eg, commercially available protein nucleic acids and synthetic sequence-specific nucleic acid polymers) or other polymers containing special bonds ( ⁇ , such polymers are present in DNA or RNA) Found Base pairing (including nucleotides having a configuration that allows base attachment)).
- They may be double-stranded DNA, single-stranded DNA, double-stranded RNA, single-stranded RNA, DNA: RNA hybrids, and may further comprise unmodified polynucleotides (or unmodified oligos).
- Nucleotides with known modifications, such as those with a label, capped, methylated, and one or more natural nucleotides substituted with analogs, as known in the art Modified with an intramolecular nucleotide, for example, having an uncharged bond (eg, methylphosphonate, phosphotriester, phosphoramidate, olebamate, etc.), a charged bond or a sulfur-containing bond (eg, phosphoro Those with thioate, phosphorodithioate, etc., such as proteins (eg, nucleases, nuclease 'inhibitors, toxins, antibodies, Those having side-chain groups such as gnal peptides, poly-L-lysine, etc., sugars (eg, monosaccharides), those having an intercurrent compound (eg, athalidine, psoralen, etc.), chelates Those containing compounds (eg, metals, radioactive metals, boron, oxid
- nucleoside may include not only purine and pyrimidine bases but also those having other modified heterocyclic bases. Such modifications may include methylated purine pyrimidines, acylated purine pyrimidines, or other heterocycles. Modified nucleotides and modified nucleotides may also be modified at the sugar moiety, e.g., where one or more hydroxyl groups have been replaced with halogens, aliphatic groups, etc., or functional groups such as ethers, amines, etc. May be converted to
- the antisense polynucleotide of the present invention is an RNA, a DNA or a modified nucleic acid (RNA, DNA).
- modified nucleic acid include sulfur derivatives of nucleic acids, thiophosphate derivatives, and polynucleoside amides, which are resistant to degradation of oligonucleoside amides, and the like.
- the antisense polynucleotide of the present invention can be designed, for example, as follows. That is, antisense polynucleotides that make antisense polynucleotides more stable in cells.
- the antisense polynucleotides of the present invention may contain altered or modified sugars, bases, or bonds, may be provided in special forms such as ribosomes, microspheres, may be applied by gene therapy, It could be given in additional form.
- polycations such as polylysine, which acts to neutralize the charge of the phosphate skeleton, and lipids, which enhance the interaction with the cell membrane or increase the uptake of nucleic acids ( Hydrophobic substances such as, for example, phospholipids, cholesterol, etc.).
- Preferred lipids for addition include cholesterol and its derivatives (eg, cholesteryl chromate, cholic acid, etc.).
- nucleic acids can be attached to the 3, or 5 'end of the nucleic acid and can be attached via bases, sugars, or intramolecular nucleoside bonds.
- Other groups include capping groups specifically located at the 3,5 or 5,5 ends of nucleic acids to prevent degradation by nucleases such as exonucleases and RNAses.
- capping groups include, but are not limited to, hydroxyl-protecting groups known in the art, including glycols such as polyethylene glycol and tetraethylene dalicol.
- the inhibitory activity of the antisense polynucleotide is determined using the transformant of the present invention, the in vivo or in vitro gene expression system of the present invention, or the in vivo or in vitro translation system of the protein or receptor used in the present invention. You can find out.
- the following are (a) a substance that inhibits the binding between the protein used in the present invention and the receptor used in the present invention, (b) a substance that inhibits the activity of the protein used in the present invention, (a receptor used in the present invention) (D) the antibody of the present invention, ( e ) the use of the antisense polynucleotide of the present invention, etc.
- the protein used in the present invention has increased expression in cancer tissue and binds to the receptor used in the present invention.
- the protein used in the present effort and the receptor used in the present invention are simultaneously expressed in cancer cells (eg, human lung cancer cells, etc.), the invasion ability induced by the receptor used in the present invention is enhanced.
- Cell proliferation is promoted in a self-contained manner (autocrine proliferation is promoted), contributing to cancer progression and malignancy.
- the receptor used in the present invention is activated (eg, phosphorylated) by the binding of the protein used in the present invention, and the mechanism leading to activation includes, for example, hepatocyte growth factor (HGF) Tyrosine kinases such as receptors are involved.
- HGF hepatocyte growth factor
- the phenomenon of promoting the growth of cancer cells as described above includes, for example, (i) binding of the protein used in the present invention to the receptor used in the present invention, (ii) activity of the protein used in the present invention (this Phosphorylation-inducing / promoting activity of the receptor used in the invention, receptor-binding activity used in the present invention, etc.), (iii) induction of activation of the receptor used in the present invention (eg, phosphorylation activity) It disappears by inhibiting the induction and promotion.
- the antibody of the present invention and the antisense polynucleotide of the present invention have an apoptosis induction / promotion action, a growth suppression action, and the like of cancer cells.
- the antibody of the present invention and the antisense polynucleotide of the present invention By binding the antibody of the present invention and the antisense polynucleotide of the present invention to the protein used in the present invention and inhibiting the expression of the protein, the growth of cancer cells is suppressed, and apoptosis is induced and promoted. .
- a substance that inhibits the binding between the protein used in the present invention and the receptor used in the present invention (b) a substance that inhibits the activity of the protein used in the present invention, (a substance that inhibits the activity of the receptor used in the present invention)
- Drugs containing the activity-inhibiting substance, (d) the antibody of the present invention (including a salt thereof) or the antisense polynucleotide of the present invention can be used with low toxicity and safety, for example, cancer (eg, colon cancer, breast cancer) , Lung cancer, prostate cancer, esophageal cancer, stomach cancer, liver cancer, biliary tract cancer, spleen cancer, kidney cancer, bladder cancer, uterine cancer, ovarian cancer, testicular cancer, thyroid cancer, kidney cancer, brain tumor, blood tumor, etc.)
- a pharmaceutical such as a therapeutic agent, a cancer cell apoptosis promoter, and a cancer cell growth inhibitor.
- the above-mentioned agent containing the antibody or the above-mentioned substance of the present invention has low toxicity and is used as it is as a liquid or as a pharmaceutical composition of an appropriate dosage form, in humans or mammals (eg, rat).
- the antibody of the present invention or the above substance may be administered as it is, or may be administered as a suitable pharmaceutical composition.
- the pharmaceutical composition used for administration may contain the antibody of the present invention or the above substance and a pharmacologically acceptable carrier, diluent or excipient.
- Such a pharmaceutical composition is provided as a dosage form suitable for oral or parenteral administration.
- compositions for parenteral administration for example, injections, suppositories, vaccines, etc. are used.
- Injections are intravenous, subcutaneous, intradermal, intramuscular, intravenous, etc. May be included.
- Such an injection can be prepared according to a known method.
- Injection preparations can be prepared, for example, by dissolving, suspending or emulsifying the antibody of the present invention or the above substance in a sterile aqueous or oily liquid commonly used for injections.
- aqueous liquid for injection for example, physiological saline, isotonic solution containing glucose and other adjuvants and the like are used, and a suitable dissolution aid, for example, alcohol (eg, ethanol), polyalcohol (Eg, propylene glycol, polyethylene glycol, nonionic surfactant [eg, polysorbate 80, HCu-50 (polyoxyethylene (50 mol) adauct of hydrogenated castor oil)), etc.].
- alcohol eg, ethanol
- polyalcohol Eg, propylene glycol, polyethylene glycol, nonionic surfactant [eg, polysorbate 80, HCu-50 (polyoxyethylene (50 mol) adauct of hydrogenated castor oil)
- sesame oil, soybean oil, etc. are used, and benzyl benzoate, benzyl alcohol, etc. may be used in combination as a dissolution aid, etc.
- the prepared injection solution is filled into an appropriate ampoule.
- compositions for oral administration include solid or liquid dosage forms, specifically tablets (including dragees and film-coated tablets), pills, granules, powders, capsules (including soft capsules), syrups Agents, emulsions, suspensions and the like.
- Such a composition is produced by a known method and may contain a carrier, diluent or excipient commonly used in the field of formulation.
- carriers and excipients for tablets for example, lactose, starch, sucrose, and magnesium stearate are used.
- Each of the above-mentioned compositions may contain another active ingredient as long as the composition does not cause an undesirable interaction with the above-mentioned antibody or substance.
- the above-mentioned parenteral or oral pharmaceutical composition is conveniently prepared in the form of a dosage unit so as to match the dosage of the active ingredient.
- dosage unit forms include, for example, tablets, pills, capsules, injections (ampoules), and suppositories.
- the content of the antibody or substance, per dosage unit form usually 5 to 500 m g, especially 5 to the injection: LOOmg, it is preferable that the antibody or agent 10 ⁇ 250mg is contained in the other dosage form .
- the dosage of the above agent varies depending on the administration target, target disease, symptoms, administration route, and the like.
- the antibody or substance of the present invention is administered once.
- the amount is usually about 0.01 to 20 mg / kg body weight, preferably about 0.1 to about 10 mg / kg body weight, more preferably about 0.1 to 5 mg / kg body weight, about 1 to 5 times a day, It is convenient to administer by intravenous injection, preferably about 1 to 3 times a day. In the case of other parenteral administration and oral administration, an equivalent dose can be administered. If the symptoms are particularly severe, the dose may be increased accordingly.
- the antibody of the present invention and the above substance may be used in combination with other drugs such as alkylating agents (eg, cyclophosphamide, ifosfamide, etc.), antagonists (eg, methotrexate, 5-fluorouracil, etc.), anticancer It may be used in combination with a sex antibiotic (eg, mitomycin, adriamycin, etc.), a plant-derived anticancer agent (eg, vincristine, vindesine, taxol, etc.), cisplatin, carboplatin, etopoxide and the like.
- the antibody of the present invention or the substance and the drug may be administered to a patient at the same time or at different times.
- the antibody of the present invention By using the antibody of the present invention, measurement of the protein or receptor used in the present invention or detection by tissue staining or the like can be performed.
- the antibody molecule itself may be used, or F (ab ') 2, Fab' or Fab fraction of the antibody molecule may be used.
- the measurement method using the antibody of the present invention is not particularly limited, and may be determined based on the amount of the antigen in the test solution (for example, the amount of the protein or receptor used in the present invention).
- Any measurement method may be used. For example, a sandwich method, a competitive method, an immunometric method, a nephelometry, etc. are used, but the sandwich method and the competitive method described later are particularly preferable in terms of sensitivity and specificity.
- the sandwich method is not particularly limited, and may be determined based on the amount of the antigen in the test solution (for example, the amount of the protein or receptor used in the present invention).
- the test solution is reacted with the insolubilized antibody of the present invention (primary reaction), and the labeled antibody of the present invention is further reacted (secondary reaction).
- primary reaction By measuring the activity of the labeling agent, the amount of the protein or receptor used in the present invention in the test solution can be quantified.
- the primary reaction and the secondary reaction may be performed at the same time or may be performed at staggered times.
- the labeling agent and the method of insolubilization can be in accordance with those described above.
- the antibody used for the solid phase antibody or the labeling antibody does not necessarily need to be one kind, but a mixture of two or more kinds of antibodies is used for the purpose of improving the measurement sensitivity and the like.
- the antibody used in the primary reaction or the secondary reaction recognizes the C-terminal of the protein or receptor used in the present invention, for example,
- the antibody used is preferably an antibody that recognizes other than the C-terminal, for example, the N-terminal.
- the ratio of the labeled protein or receptor used in the present invention bound to the antibody, the test solution and the labeled protein or receptor used in the present invention in a competitive reaction with the antibody of the present invention is quantified.
- This reaction method is performed using, for example, a solid phase method.
- an anti-mouse IgG antibody manufactured by ICN / CAPPEL
- the plate on which the immobilized antibody is present is labeled with (i) the antibody of the present invention, and (ii) labeled with HRP.
- HRP activity adsorbed on the solid phase is measured, and the protein used in the present invention is measured.
- the protein or receptor is quantified.
- an antigen in a test solution and a solid-phased antigen are subjected to a competitive reaction with a fixed amount of the labeled antibody of the present invention, and then the solid phase and the liquid phase are separated.
- the amount of label in either phase is measured to determine the amount of antigen in the test solution.
- Nephrometry measures the amount of insoluble sediment resulting from an antigen-antibody reaction in a gel or solution. Even when the amount of the antigen in the test solution is small and only a small amount of sediment is obtained, a laser Nefmeter method utilizing laser scattering is preferably used.
- radioisotope an enzyme, a fluorescent substance, a luminescent substance, a lanthanide element and the like are used as a labeling agent used in a measuring method using a labeling substance.
- radioisotopes include [ 125 ⁇ ], [ 131 ⁇ ], [3 ⁇ 4], and C 14 c
- the enzyme those having a stable and high specific activity are preferable, for example, i3-galactosidase,] 3-gunorecosidase, anorecaliphosphatase, peroxidase, malate dehydrogenase, etc.
- the luminescent substance include cyanine fluorescent dyes (eg, Cy2, Cy3, Cy5, Cy5.5, Cy7 (manufactured by Amersham Bioscience)), fluorescamine, fluorescein isothiocyanate, and the like.
- cyanine fluorescent dyes eg, Cy2, Cy3, Cy5, Cy5.5, Cy7 (manufactured by Amersham Bioscience)
- fluorescamine fluorescein isothiocyanate
- luminol, luminol derivatives, luciferin, lucigenin and the like can be mentioned.
- a biotin-avidin system can be used for binding the antibody and the labeling agent.
- the insolubilization of the antigen or antibody physical adsorption may be used, or a method using a chemical bond usually used for insolubilizing and immobilizing proteins or enzymes may be used.
- the carrier include insoluble polysaccharides such as agarose, dextran, and cellulose, and synthetic resins such as polystyrene, polyacrylamide, and silicon, and glass.
- the antibody of the present invention can quantify the protein or receptor used in the present invention with high sensitivity, the physiological function of the protein or receptor used in the present invention is further elucidated, and It is useful for diagnosis of diseases involving the protein or receptor used.
- Cancer e.g., colon cancer, breast cancer, lung cancer, prostate cancer, esophageal cancer, stomach cancer, liver cancer, biliary tract cancer, spleen cancer, renal cancer, bladder cancer, uterine cancer, ovarian cancer, testicular cancer, thyroid cancer, knee cancer, Brain tumor, hematoma, etc.
- Cancer e.g., colon cancer, breast cancer, lung cancer, prostate cancer, esophageal cancer, stomach cancer, liver cancer, biliary tract cancer, spleen cancer, renal cancer, bladder cancer, uterine cancer, ovarian cancer, testicular cancer, thyroid cancer, knee cancer, Brain tumor, hematoma, etc.
- the protein used in the present invention has increased expression in cancer tissues and binds to the receptor used in the present invention.
- Protein used in the present invention and used in the present invention Since the receptor used is simultaneously expressed in cancer cells (eg, human lung cancer cells, etc.), the proliferation of cells with enhanced invasion induced by the receptor used in the present invention is self-contained. Occurs (promotes autocrine growth) and contributes to cancer progression-malignancy.
- the receptor used in the present invention is activated (eg, phosphorylated) by the binding of the protein used in the present invention.
- the mechanism leading to activation includes, for example, hepatocyte growth factor (HGF ) Tyrosine kinases such as receptors are involved.
- HGF hepatocyte growth factor
- the above-mentioned phenomenon of promoting the growth of cancer cells includes, for example, (i) binding of the protein used in the present invention to the receptor used in the present invention, (ii) activity of the protein used in the present invention (used in the present invention) (Iii) induction of receptor phosphorylation (promoting activity, receptor binding activity used in the present invention, etc.), (iii) induction of receptor activation used in the present invention (eg, induction and promotion of phosphorylated activity, etc.) Inhibition results in the disappearance of cancer cells, inhibiting the growth of cancer cells and inducing apoptosis.
- the compound or a salt thereof that inhibits the activity of the protein or receptor used in the present invention includes, for example, cancer (eg, colon cancer, breast cancer, lung cancer, prostate cancer, esophageal cancer, gastric cancer, liver cancer, biliary tract cancer, Spleen cancer, kidney cancer, bladder cancer, uterine cancer, ovarian cancer, testicular cancer, thyroid cancer, knee cancer, brain tumor, blood tumor, etc.)
- cancer eg, colon cancer, breast cancer, lung cancer, prostate cancer, esophageal cancer, gastric cancer, liver cancer, biliary tract cancer, Spleen cancer, kidney cancer, bladder cancer, uterine cancer, ovarian cancer, testicular cancer, thyroid cancer, knee cancer, brain tumor, blood tumor, etc.
- Prevention and treatment agent, cancer cell apoptosis promoter, cancer cell growth suppression It can be used as an agent and the like.
- the protein or receptor used in the present invention is useful as a reagent for screening a substance that inhibits the activity of the protein or receptor of the present invention, respectively.
- the present invention provides a method for screening a substance that inhibits the activity of the protein or receptor used in the present invention, which comprises using the protein or receptor used in the present invention.
- the protein of the present invention and the receptor used in the present invention may be used as a method for screening a substance that inhibits the activity of the protein used in the present invention (eg, the receptor binding activity used in the present invention). It is expressed in animal cells as a tagged recombinant protein. As the tag, FLAG, His, V5, myc, HA and the like are used, and the tag added to the protein of the present invention (Tag A) is different from the tag added to the receptor used in the present invention (Tag B) Use something Yes.
- the tag FLAG, His, V5, myc, HA and the like are used, and the tag added to the protein of the present invention (Tag A) is different from the tag added to the receptor used in the present invention (Tag B) Use something Yes.
- An antibody against tag B is used to immunize (i) a mixture of the above-mentioned tag A-added protein and the above-mentioned tag B-added receptor, or (ii) a test compound, a mixture of the above-mentioned tag A-added protein and the above-mentioned tag B-added receptor.
- the amount of the protein used in the present invention bound to the receptor used in the present invention was measured by performing Western blotting operation on the resulting precipitate by using an antibody against tag A. Compare cases (i) and (ii).
- a substance that inhibits the activity of the protein used in the present invention for example, a tag (eg, FLAG, His, V5, myc, HA, etc.) at the C-terminus and expressing the receptor used in the present invention in animal cells as a recombinant protein, (i) the protein used in the present invention, or (ii) the test conjugate.
- a tag eg, FLAG, His, V5, myc, HA, etc.
- the amount is measured by a known method (eg, stamplot method) using an anti-phosphorylated tyrosine antibody or the like, and the results are compared between (i) and (ii) above.
- the activity of inducing and promoting phosphorylation may be performed according to a method known per se, for example, the method described in Methods in Enzymology, vol. 200, pp. 98-107, 1991, or a method analogous thereto.
- the activity of the protein used in the present invention in the case of the above (ii) is about 20% or more, preferably 30% or more, more preferably about 50% or more compared with the case of the above (i).
- the test compound to be inhibited can be selected as a substance that inhibits the activity of the protein used in the present invention.
- Specific examples of the method for screening a substance that inhibits the activity of a receptor (eg, phosphorylation activity) used in the present invention include, for example, a tag (eg, FLAG, His, V5, myc, HA, etc.) Is expressed in animal cells as a recombinant protein, and (i ') the protein used in the present invention, or (ii') the protein used in the present invention.
- a tag eg, FLAG, His, V5, myc, HA, etc.
- the activity of the receptor used in the present invention in the case of the above ( ⁇ ′) is about 20% or more, preferably 30% or more, more preferably about 20% or more of that in the above (i ′).
- a test compound that inhibits 50% or more can be selected as a compound that inhibits the activity of the receptor used in the present invention.
- Examples of the cells having the ability to produce the protein or receptor used in the present invention include, for example, a host (plasmid) transformed with a vector containing a DNA encoding the protein or receptor used in the present invention. (Transformant) is used.
- a host for example, animal cells such as COS 7 cells, CHO cells, and HEK293 cells are preferably used.
- a transformant in which the protein of the present invention is expressed on a cell membrane by culturing by the method described above is preferably used.
- the method for culturing cells capable of expressing the protein of the present invention is the same as the above-described method for culturing the transformant of the present invention.
- Test compounds include, for example, peptides, proteins, antibodies, non-peptidic compounds, synthetic compounds, fermentation products, cell extracts, plant extracts, animal tissue extracts, and plasma.
- substances that inhibit the expression of the protein or receptor gene used in the present invention include, for example, cancer (eg, colon cancer, breast cancer) , Lung cancer, prostate cancer, esophageal cancer, stomach cancer, liver cancer, biliary tract cancer, spleen cancer, kidney cancer, bladder cancer, uterine cancer, ovarian cancer, testis cancer, thyroid cancer, spleen cancer, brain tumor, blood tumor, etc. It can be used as a preventive / therapeutic agent, a cancer cell apoptosis promoter, a cancer cell growth inhibitor, etc.
- the polynucleotide eg, DNA
- the polynucleotide eg, DNA
- the polynucleotide encoding the protein or receptor used in the present invention is used for screening a compound or a salt thereof that inhibits the expression of the protein or receptor gene used in the present invention.
- Useful as a reagent Useful as a reagent.
- the screening methods include (iii) culturing cells capable of producing the protein or receptor used in the present invention, and (iv) producing the protein or receptor used in the present invention in the presence of a test compound. Have the ability There is a screening method characterized by performing a comparison with the case where cells are cultured.
- the expression level of the gene in (iii) and (iv) (specifically, the amount of the protein or receptor used in the present invention or the amount of the protein or receptor used in the present invention) Measure the amount of mRNA and compare.
- test compound and cells having the ability to produce the protein of the present invention include the same as those described above.
- the amount of protein can be measured by a known method, for example, using the antibody of the present invention to measure the protein present in a cell extract or the like according to a method such as Western analysis, ELISA, or a method analogous thereto. it can.
- the amount of mRNA is measured by a known method, for example, as a probe, the base sequence represented by SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 or SEQ ID NO: 35; Northern hybridization using a nucleic acid containing a part thereof, or a nucleotide sequence represented by SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 11 or SEQ ID NO: 35 as a primer Alternatively, it can be measured according to a PCR method using a nucleic acid containing a part thereof or a method analogous thereto.
- a test compound that inhibits the expression of the gene in the case of the above (iv) by about 20% or more, preferably 30% or more, more preferably about 50% or more as compared with the case of the above (iii) can be selected as compounds that inhibit the expression of the protein or receptor gene used in the present invention.
- the screening kit of the present invention contains the protein or receptor used in the present invention, or a cell capable of producing the protein or receptor used in the present invention.
- Substances obtained using the screening method or the screening kit of the present invention include the test compounds described above, for example, peptides, proteins, non-peptidic compounds, synthetic compounds, fermentation products, cell extracts, plant extracts, Selected from animal tissue extract, plasma, etc.
- the salt those similar to the aforementioned salts of the protein of the present invention are used.
- the substance obtained by using the screening method or the screening kit of the present invention is used as the above-mentioned agent, it can be formulated according to a conventional method.
- the composition for oral administration or parenteral administration is as described above.
- the same compositions as those described in [1] can be mentioned, and they can be produced and used in the same manner. [4] Gene diagnostics
- the polynucleotide (eg, DNA) encoding the protein or receptor used in the present invention can be used, for example, by using it as a probe to produce a human or warm-blooded animal (eg, rat, mouse, guinea pig, egret, bird, sheep).
- DNA or abnormal DNA encoding the protein or receptor used in the present invention or a partial peptide thereof in pigs, pigs, pests, pomas, cats, dogs, monkeys, chimpanzees, etc. Abnormality) can be detected, and thus is useful as a gene diagnostic agent for, for example, damage, mutation or decreased expression of the DNA or mRNA, and increase or excessive expression of the DNA or mRNA.
- the above-described genetic diagnosis can be performed, for example, by the well-known Northern hybridization or PCR-SSCP method (Genomics, Vol. 5, pp. 874-879 (1989), Proceedings of the National Acaaemy of Sciences of the United States of America, ⁇ 8 ⁇ , 2766-2770 (1989)).
- cancer eg, colorectal cancer, breast cancer, lung cancer, prostate cancer, esophagus
- stomach cancer liver cancer, biliary tract cancer, spleen cancer, kidney cancer, bladder cancer, uterine cancer, ovarian cancer, testicular cancer, thyroid cancer, kidney cancer, brain tumor, blood tumor, etc.
- the antisense polynucleotide of the present invention has low toxicity, it can suppress the function or action of the protein or receptor used in the present invention and the DNA encoding the same in vivo and induce apoptosis of cancer cells.
- Eg ⁇ eg, colon cancer, breast cancer, lung cancer, prostate cancer, esophagus cancer, stomach cancer, liver cancer, biliary tract cancer, spleen cancer, kidney cancer, bladder cancer, uterine cancer, ovarian cancer, testicular cancer, thyroid cancer, victory cancer Cancer, brain tumor, blood tumor Prophylactic and therapeutic agents, cancer cell apoptosis promoters, cancer cell proliferation inhibitors, etc.
- the above antisense polynucleotide When used as the above agent or the like, it can be formulated and administered according to a method known per se.
- the above-mentioned antisense polynucleotide is used alone or in a suitable vector such as a retrovirus vector, an adenovirus vector, an adenovirus associated virus vector, etc. Can be administered orally or parenterally to mammals (eg, rats, puppies, sheep, pigs, puppies, cats, dogs, monkeys, etc.).
- the antisense polynucleotide can be administered as it is or in the form of a formulation together with a physiologically acceptable carrier such as a scavenger to promote uptake, and administered with a gene gun or a catheter such as a hydrogel catheter. Alternatively, they can be aerosolized and administered topically into the trachea as an inhalant.
- the antisense polynucleotide is formulated alone or in combination with a carrier such as ribosome (injection), and is intravenously, subcutaneously, etc. May be administered.
- the dose of the antisense polynucleotide varies depending on the target disease, the subject of administration, the route of administration, and the like.
- the antisense polynucleotide of the present invention is administered for the purpose of treating breast cancer, it is generally used in adults. (Body weight 60 kg), about 0.1 to 100 rag of the antisense polynucleotide is administered per day.
- the antisense polynucleotide can also be used as a diagnostic oligonucleotide probe for examining the presence of the DNA of the present invention in tissues or cells and the state of its expression.
- RNA containing a part of the RNA encoding the protein or the receptor used in the present invention, and containing a part of the RNA encoding the protein or the receptor used in the present invention Liposomes and the like can also suppress the expression of the protein or receptor gene used in the present invention, and can suppress the function of the protein or receptor used in the present invention or the DNA encoding the same in vivo.
- cancer eg, colon cancer, breast cancer, lung cancer, prostate cancer, esophagus cancer, stomach cancer, liver cancer, biliary tract cancer, spleen cancer, kidney cancer, bladder cancer, uterine cancer, ovarian cancer, testicular cancer, thyroid cancer
- a preventive / therapeutic agent for spleen cancer, brain tumor, blood tumor, etc. an apoptosis promoter for cancer cells, a cancer cell growth inhibitor, etc.
- the double-stranded RNA can be produced by designing based on the sequence of the polynucleotide of the present invention according to a known method (eg, Nature, 411, 494, 2001).
- a ribozyme can be designed and manufactured based on the sequence of the polynucleotide of the present invention according to a known method (eg, TRENDS in Molecular Medicine, vol. 7, p. 221, 2001). For example, it can be produced by linking a known lipozyme to a part of the RNA encoding the protein of the present invention. Examples of a part of the RNA encoding the protein of the present invention include a part (RNA fragment) close to the cleavage site on the RNA of the present invention, which can be cleaved by a known ribozyme.
- RNA or lipozyme When the above-described double-stranded RNA or lipozyme is used as the above agent, it can be formulated and administered in the same manner as the antisense polynucleotide.
- compositions containing protein or receptor used in the present invention are overexpressed in cancer, and the receptor used in the present invention is also expressed in cancer cells.
- the protein or receptor used in the present invention to activate the patient's immune system can also be used as a cancer vaccine.
- adoptive immunotherapy which comprises culturing strong antigen-presenting cells (eg, dendritic cells) in the presence of the protein or receptor used in the present invention, phagocytosing the protein, and then returning it to the patient's body.
- strong antigen-presenting cells eg, dendritic cells
- the dendritic cells returned to the body can kill cancer cells by inducing and activating cancer antigen-specific cytotoxic T cells.
- the protein or receptor of the present invention may be, for example, a cancer (eg, colon cancer, breast cancer, lung cancer, prostate cancer, esophageal cancer, stomach cancer, liver cancer, biliary tract cancer, spleen cancer, kidney cancer, bladder cancer, ovarian cancer, ovary)
- a cancer eg, colon cancer, breast cancer, lung cancer, prostate cancer, esophageal cancer, stomach cancer, liver cancer, biliary tract cancer, spleen cancer, kidney cancer, bladder cancer, ovarian cancer, ovary
- a vaccine preparation for the prevention or treatment of cancer testicular cancer, thyroid cancer, spleen cancer, spleen cancer, brain tumor, hematological tumor, etc., safely, in mammals (eg, human, monkey, mouse, rat, rabbit, pig) )
- the vaccine preparation usually contains the protein or receptor used in the present invention and a physiologically acceptable carrier.
- the carrier for example, water, saline
- Liquid carriers such as (including physiological saline), buffers (eg, phosphate buffer), alcohols (eg, ethanol).
- the vaccine preparation can be prepared according to a usual vaccine preparation manufacturing method.
- the protein or receptor used in the present invention is dissolved or suspended in a physiologically acceptable carrier.
- the protein used in the present invention and a physiologically acceptable carrier may be separately prepared, and these may be mixed and used at the time of use.
- Pectin preparations include, in addition to the protein or receptor used in the present invention and a physiologically acceptable carrier, adjuvants (eg, aluminum hydroxide gel, serum albumin, etc.), preservatives (eg, thimerosal, etc.), pain relief Agents (eg, glucose, benzyl alcohol, etc.). Further, in order to promote the production of antibodies against the protein or receptor used in the present invention, for example, cytotoxicity (eg, interleukins such as interleukin-12, interferons such as interferon-1 ⁇ , etc.) is further added. You may mix. When used as a vaccine formulation, the protein or receptor used in the present invention may be used as an active form, or may be modified to increase antigenicity. Denaturation is usually performed by heat treatment or treatment with a protein denaturant (eg, formalin, guanidine hydrochloride, urea).
- a protein denaturant eg, formalin, guanidine hydrochloride, urea
- the resulting vaccine preparation has low toxicity, and may be usually administered as an injection, for example, subcutaneously, intradermally, or intramuscularly, or may be locally administered to or near a cancer cell mass.
- the dose of the protein or receptor used in the present invention varies depending on, for example, the target disease, the subject to be administered, the administration route, and the like.
- the dose is usually about 0.1 to 300 mg, preferably about 100 to 300 mg per dose.
- the vaccine may be administered only once, but to increase antibody production,
- the pectin preparation can also be administered 2-4 times, with an interval of between week and about 6 months.
- the present invention relates to a DNA encoding an exogenous protein or receptor used in the present invention (hereinafter abbreviated as an exogenous DNA of the present invention) or a mutant DNA thereof (hereinafter abbreviated as an exogenous mutant DNA of the present invention).
- the present invention provides a non-human mammal having
- the non-human mammal having the exogenous DNA of the present invention or the mutant DNA thereof includes an unfertilized egg, a fertilized egg, a germ containing a spermatozoa and its progenitor cells.
- an unfertilized egg preferably at the stage of embryo development in non-human mammal development (more preferably at the stage of single cells or fertilized egg cells and generally before the 8-cell stage), calcium phosphate method, electric pulse method It can be produced by transferring the target DNA by a ribofusion method, an aggregation method, a microinjection method, a particle gun method, a DEAE-dextran method, or the like.
- the target exogenous DNA of the present invention can be transferred to somatic cells, organs of living organisms, tissue cells, and the like, and used for cell culture, tissue culture, and the like.
- the transgenic animal of the present invention can also be produced by fusing the above-mentioned germinal cells with a cell fusion method known per se.
- non-human mammal for example, porcupine, pig, hidge, goat, magpie, dog, cat, guinea pig, hamster, mouse, rat and the like are used.
- rodents with relatively short ontogeny and biological cycle in terms of the creation of disease animal model systems, and rodents that are easy to breed, especially mice The strain may be BSCSFi strain, BDF strain, B6D2F strain, BALBZc strain, ICR strain, etc.) or rat (eg For example, Wister, SD, etc.) are preferable.
- mammal in the recombinant vector that can be expressed in mammals, human and the like can be mentioned in addition to the above-mentioned non-human mammals.
- the exogenous DNA of the present invention refers not to the DNA of the present invention originally possessed by a non-human mammal but to the DNA of the present invention once isolated and extracted from a mammal.
- mutant DNA of the present invention those in which a mutation (for example, mutation) has occurred in the base sequence of the original DNA of the present invention, specifically, base addition, deletion, substitution with another base Such DNAs are used, and abnormal DNAs are also included.
- the abnormal DNA means a DNA that expresses an abnormal protein of the present invention.
- a DNA that expresses a protein that suppresses the function of the normal protein of the present invention is used.
- the exogenous DNA of the present invention may be derived from a mammal which is the same or different from the target animal.
- a mammal which is the same or different from the target animal.
- the human DNA of the present invention when transferred, it may be derived from various mammals having the DNA of the present invention having a high homology to the human DNA (eg, egrets, dogs, cats, monoremots, hamsters, rats, mice, etc.).
- the DNA is constructed by microinjecting the DNA construct of the present invention (eg, a vector) downstream of various promoters capable of expressing DNA into a fertilized egg of a target mammal, for example, a mouse fertilized egg.
- a DNA-transferred mammal that highly expresses the DNA of the present invention can be created.
- Examples of the expression vector of the protein of the present invention include a plasmid derived from Escherichia coli, a plasmid derived from Bacillus subtilis, a plasmid derived from yeast, a bacteriophage such as ⁇ phage, a retrovirus such as Moroni monoleukemia virus, a vaccinia virus or a paculovirus.
- animal viruses such as Among them, a plasmid derived from Escherichia coli, a plasmid derived from Bacillus subtilis or a plasmid derived from yeast are preferably used.
- promoters that regulates the expression of DNA include (i) viruses (eg, Simian virus, cytomegalovirus, Moroni leukemia virus, . Virus, breast cancer virus, poliovirus, etc.), and (ii) promoters derived from various mammals (eg, humans, puppies, dogs, cats, guinea pigs, hamsters, rats, mice), for example, Albumin, insulin II, peroplakin II, elastase, erythropoietin, endothelin, muscle creatine kinase, glial fibrillary acidic protein, daltathione S-transferase, platelet-derived growth factor j3, keratin Kl, K10 and 414, Lagen type I and type II, cyclic AMP-dependent protein kinase 3 I subunit, dystrophin, tartrate-resistant alfa phosphatase, atrial sodium diuretic factor, endothelial receptor thymic synkin
- a cytomegalovirus promoter capable of high expression throughout the whole body a human peptide chain elongation factor 1a (EF-1a) promoter, a human and a chicken 3-actin promoter, and the like are preferable.
- EF-1a human peptide chain elongation factor 1a
- the vector preferably has a sequence that terminates transcription of the messenger RNA of interest in the DNA-transferring mammal (generally called terminator).
- terminator DNAs derived from viruses and various mammals
- the SV40 terminator of Simian virus or the like is preferably used.
- the splicing signal of each DNA, the enhancer region, a part of the intron of eukaryotic DNA, etc. are used to further express the target exogenous DNA at 5, 5, upstream of the promoter region, between the promoter region and the translation region, or Translation area It is also possible to connect 3 'downstream according to the purpose.
- the normal translation region of the protein of the present invention may be a human or various mammals (for example, egrets, dogs, cats, monkeys /bone, hamsters, rats, mice, etc.) derived from monocytes, kidneys, thyroid cells, fibers
- Complementary DNA prepared by known methods as whole or part of genomic DNA from blast cell-derived DNA and various commercially available genomic DNA libraries or from liver, kidney, thyroid cell, and fibroblast-derived RNA It can be obtained as a raw material.
- an exogenous abnormal DNA can produce a translation region obtained by mutating the translation region of a normal protein obtained from the above cells or tissues by point mutagenesis.
- the translation region can be prepared as a DNA construct that can be expressed in a transgenic animal by a conventional DNA engineering technique in which it is ligated downstream of the above promoter and, if desired, upstream of the transcription termination site.
- Transfer of the exogenous DNA of the present invention at the fertilized egg cell stage is ensured to be present in all germ cells and somatic cells of the target mammal.
- the presence of the exogenous DNA of the present invention in the germinal cells of the transgenic animal after the DNA transfer indicates that all of the progeny of the transgenic animal and the exogenous DNA of the present invention will be present in all of the embryonic and somatic cells. It means to keep NA.
- the progeny of this type of animal that has inherited the exogenous DNA of the present invention has the exogenous DNA of the present invention in all of its germinal and somatic cells.
- the non-human mammal to which the exogenous normal DNA of the present invention has been transferred is confirmed to stably maintain the exogenous DNA by mating, and is subcultured as a DNA-bearing animal in a normal breeding environment. I can do it.
- Transfer of the exogenous DNA of the present invention at the fertilized egg cell stage is ensured to be present in excess in all germ cells and somatic cells of the target mammal.
- Excessive presence of the exogenous DNA of the present invention in the germinal cells of the animal after transfer of DNA indicates that all of the offspring of the animal produce the exogenous DNA of the present invention in all of its germinal and somatic cells.
- Means to have The offspring of this type of animal that inherited the exogenous DNA of the present invention include homozygous animals that have the introduced DNA in excess of the exogenous DNA of the present invention in both their germ cells and somatic cells on both homologous chromosomes. Get this sex By crossing the animals, all offspring can be bred and passaged so as to have the DNA in excess.
- the normal DNA of the present invention is highly expressed, and the function of the endogenous normal DNA is ultimately promoted by promoting the function of endogenous normal DNA. It may develop hyperfunction and can be used as a disease model animal. For example, using the normal DNA-transferred animal of the present invention, it is possible to elucidate the pathological mechanism of the hyperactivity of the protein of the present invention and diseases associated with the protein of the present invention, and to examine a method for treating these diseases. It is possible.
- a preventive / therapeutic agent for a disease associated with the protein of the present invention for example, a cancer ( Examples: colorectal cancer, ⁇ cancer, lung cancer, prostate cancer, esophageal cancer, stomach cancer, liver cancer, biliary tract cancer, spleen cancer, renal cancer, bladder cancer, uterine cancer, ovarian cancer, testicular cancer, thyroid cancer, knee cancer, It can also be used for screening tests for prophylactic and therapeutic agents for brain tumors and blood tumors.
- a cancer Examples: colorectal cancer, ⁇ cancer, lung cancer, prostate cancer, esophageal cancer, stomach cancer, liver cancer, biliary tract cancer, spleen cancer, renal cancer, bladder cancer, uterine cancer, ovarian cancer, testicular cancer, thyroid cancer, knee cancer, It can also be used for screening tests for prophylactic and therapeutic agents for brain tumors and blood tumors.
- the non-human mammal having the exogenous abnormal DNA of the present invention was confirmed to stably maintain the exogenous DNA by mating, and was subcultured as an animal having the exogenous DNA in a normal breeding environment. You can do it. Further, the desired foreign DNA can be incorporated into the above-mentioned plasmid and used as a raw material.
- the DNA construct with the promoter can be prepared by ordinary DNA engineering techniques. The transfer of the abnormal DNA of the present invention at the fertilized egg cell stage is ensured to be present in all germ cells and somatic cells of the target mammal.
- the presence of the abnormal DNA of the present invention in the germinal cells of the animal produced after the transfer of the DNA means that all the offspring of the animal produced have the abnormal DNA of the present invention in all of the embryonic and somatic cells.
- the progeny of this type of animal that inherits the exogenous DNA of the present invention has the abnormal DNA of the present invention in all of its germinal and somatic cells.
- a homozygous animal having the introduced DNA on both homologous chromosomes is obtained, and by crossing the male and female animals, it is possible to breed so that all offspring have the DNA.
- the non-human mammal having the abnormal DNA of the present invention has a high level of expression of the abnormal DNA of the present invention, and ultimately develops by inhibiting the function of endogenous normal DNA.
- the protein may become functionally inactive refractory, and can be used as a disease model animal. For example, using the abnormal DNA-transferred animal of the present invention, it is possible to elucidate the pathological mechanism of the function-inactive refractory of the protein of the present invention and to examine a method for treating this disease.
- the abnormal DNA highly expressing animal of the present invention can be used to inhibit the function of the normal protein by the abnormal protein of the present invention (dominant negative action) in the function-inactive refractory disease of the protein of the present invention. ) Is a model for elucidating.
- a preventive / therapeutic agent for the protein of the present invention or a functionally inactive refractory disease for example, cancer (eg, colon cancer, breast cancer, lung cancer, prostate cancer, esophageal cancer, stomach cancer, liver cancer, biliary tract cancer, spleen cancer, kidney cancer, bladder cancer, uterine cancer, ovarian cancer, testicular cancer, thyroid cancer, knee cancer , Brain tumors, blood tumors, etc.) It can also be used for screening tests of therapeutic agents.
- cancer eg, colon cancer, breast cancer, lung cancer, prostate cancer, esophageal cancer, stomach cancer, liver cancer, biliary tract cancer, spleen cancer, kidney cancer, bladder cancer, uterine cancer, ovarian cancer, testicular cancer, thyroid cancer, knee cancer , Brain tumors, blood tumors, etc.
- the protein of the present invention can be identified, its relationship with apoptosis, differentiation or proliferation, or its signal transduction mechanism can be examined, and its abnormality can be examined. It is an effective research material for elucidation.
- the DNA transgenic animal of the present invention in order to develop a therapeutic agent for diseases associated with the protein of the present invention, including the inactive refractory type of the protein of the present invention, using the DNA transgenic animal of the present invention, the above-mentioned test was conducted. It is possible to provide an effective and rapid screening method for the therapeutic agent for the disease by using the method and the quantitative method. In addition, using the transgenic animal of the present invention or the exogenous DNA expression vector of the present invention, it is possible to examine and develop a method for treating DNA associated with the protein of the present invention.
- the present invention provides a non-human mammal embryonic stem cell in which DNA (DNA of the present invention) encoding the protein or receptor used in the present invention is inactivated, and a non-human mammal deficient in expression of the DNA of the present invention. .
- Non-human mammal according to item (6) (8) the non-human mammal according to (6), wherein the non-human mammal is a rodent;
- test compound is administered to the animal described in (7) and the expression of a reporter gene is detected.
- a screening method is provided.
- the non-human mammalian embryonic stem cells in which the DNA of the present invention has been inactivated may be obtained by artificially mutating the DNA of the present invention possessed by the non-human mammal to suppress the DNA expression ability, or By substantially losing the activity of the protein of the present invention encoded by the DNA, the DNA does not substantially have the ability to express the protein of the present invention (hereinafter, referred to as the knockout DNA of the present invention).
- ES cells Non-human mammalian embryonic stem cells
- non-human mammal the same one as described above is used.
- the method of artificially mutating the DNA of the present invention can be performed, for example, by deleting a part or all of the DNA sequence and inserting or substituting another DNA sequence by a genetic engineering technique.
- the knockout DNA of the present invention may be prepared by, for example, shifting the codon reading frame or disrupting the function of the promoter or exon by these mutations.
- non-human mammalian embryonic stem cells in which the DNA of the present invention has been inactivated include, for example, The DNA of the present invention possessed by a non-human mammal is isolated, and its exon portion is a drug resistance gene represented by a neomycin resistance gene, a hygromycin resistance gene, or lacZ (i3_galactosidase gene), cat (chloramphene).
- DNA strand having a D NA sequence was constructed so as to destroy the child (hereinafter simply referred to as targeting vector) into the chromosomes of the animal by homologous recombination technique, the obtained ES cells DNA rooster B sequence on Southern hybridization hybridization or targeting vector using the DNA sequence on or near the DNA of the present invention as a probe and the DNA sequence of the neighboring region other than the DNA of the present invention used for the production of the targeting vector It can be obtained by analyzing by a PCR method using the sequence as a primer and selecting the knockout ES cells of the present invention.
- a reporter gene such as the nicole acetyltransferase gene, or a DNA sequence that terminates gene transcription in the introns between exons (eg, po1yA addition) Signal, etc.
- ES cells from which the DNA of the present invention is inactivated by the homologous recombination method or the like for example, those already established as described above may be used, or according to the known Evans and Kaufma method. May be newly established.
- mouse ES cells currently, 129 ES cells are generally used, but since the immunological background is not clear, an alternative pure immunological and genetically
- BDF mice C57BL6 whose C57BLZ6 mice and C57BL / 6 have improved the number of eggs collected by crossing with DBA / 2 (C57BL
- C57BL It is also possible to use a mouse established using a combination of C / 6B and DB AZ2, etc.
- the BDFi mouse has the advantage of large number of eggs collected and its eggs are strong, and also has the advantage of using C57B LZ6 mouse.
- the ES cells obtained by using these cells can be used to backcross the C57BLZ6 mouse to the C57BLZ6 mouse by back-crossing with the C57B LZ6 mouse when creating a disease model mouse. It can be used advantageously because it is possible.
- blastocysts are generally used on the 3.5th day after fertilization. An embryo can be obtained.
- male ES cells are generally more convenient for producing germline chimeras. It is also desirable to discriminate between males and females as soon as possible in order to reduce the complexity of culturing.
- An example of a method for determining the sex of ES cells is a method of amplifying and detecting a gene in the sex-determining region on the Y chromosome by PCR.
- this method conventionally, for example G-banding method, requires about 10 6 cells for karyotype analysis, since suffices ES cell number of about 1 colony (about 50), culture Primary selection of ES cells in the early stage can be performed by gender discrimination. Yes, by enabling the selection of male cells at an early stage, the labor at the beginning of culture can be greatly reduced.
- the secondary selection can be performed, for example, by confirming the number of chromosomes by the G-banding method.
- the embryonic stem cell line obtained in this way usually has very good growth potential, but it must be carefully subcultured because it tends to lose its ability to generate individuals.
- a suitable feeder cell such as STO fibroblast, LIF ⁇ 10000 U / ml
- carbon dioxide incubator preferably 5% carbon dioxide, 95% air or 5% oxygen, 5% Culture at about 37 ° C with carbon dioxide gas and 90% air at the time of subculture.
- trypsin / EDTA solution usually 0.001-0.5% trypsin / 0.1-5 mM EDTA (Preferably, about 0.1% trypsin / 1 mM EDTA)
- Such subculture is usually performed every 1 to 3 days. At this time, it is desirable to observe the cells and discard the cultured cells if morphologically abnormal cells are found. ⁇
- ES cells can be cultured in monolayers up to high densities or in suspension cultures to form cell clumps under appropriate conditions to produce various types of cells such as parietal, visceral, and cardiac muscles.
- DNA of the present invention obtained by separating ES cells of the present invention.
- Expression-deficient cells are useful in in vitro cell biology studies of the proteins of the invention.
- the non-human mammal deficient in DNA expression of the present invention can be distinguished from a normal animal by measuring the mRNA level of the animal using a known method and indirectly comparing the expression level.
- the non-human mammal the same one as described above is used.
- the targeting vector prepared as described above is introduced into mouse embryonic stem cells or mouse egg cells, and the DNA of the present invention as one of the targeting vectors is inactivated by the introduction.
- the DNA of the present invention can be knocked out. .
- Cells in which the DNA of the present invention has been knocked out are combined with a DNA sequence on a Southern hybridization analysis or targeting vector using the DNA sequence on or near the DNA of the present invention as a probe, and a targeting vector.
- the determination can be made by PCR analysis using a primer and a DNA sequence of a neighboring region other than the DNA of the present invention derived from the used mouse.
- a cell line in which the DNA of the present invention has been inactivated by gene homologous recombination is cloned, and the cells are cultured at an appropriate time, for example, at the 8-cell stage of non-human cells.
- the chimeric embryo is injected into a mammalian embryo or a blastocyst, and the resulting chimeric embryo is transplanted into the uterus of the pseudopregnant non-human mammal.
- the produced animal is a chimeric animal composed of both the cells having the normal DNA locus of the present invention and the cells having the artificially changed DNA locus of the present invention.
- all tissues are artificially mutated from a population obtained by crossing such a chimeric individual with a normal individual. Can be obtained by, for example, selecting an individual composed of cells having the DNA locus of the present invention to which the DNA is added by, for example, judging coat color.
- the individuals obtained in this manner are usually individuals with a heterozygous expression of the protein of the present invention, which are crossed with individuals with a heterozygous expression of the protein of the present invention.
- An individual having a deficiency in homoexpression of the protein can be obtained.
- a transgenic non-human mammal having a targeting vector introduced into a chromosome can be obtained by injecting a DNA solution into the egg cell nucleus by a microinjection method. Compared to non-human mammals, it can be obtained by selecting those having a mutation in the DNA locus of the present invention by gene homologous recombination. In the individual knocked out with the DNA of the present invention in this manner, the animal individuals obtained by the crossing should be confirmed to be knocked out of the DNA, and then reared in a normal breeding environment. Can be.
- germline acquisition and retention may be performed in accordance with a standard method. That is, by crossing male and female animals having the inactivated DNA, homozygous animals having the inactivated DNA on both homologous chromosomes can be obtained. The obtained homozygous animal can be efficiently obtained by rearing the mother animal in a state where one normal individual and plural homozygous animals are obtained. By mating male and female heterozygous animals, homozygous and heterozygous animals having the inactivated DNA are bred and subcultured.
- the non-human mammalian embryonic stem cells in which the DNA of the present invention has been inactivated are very useful for producing the non-human mammal deficient in expression of the DNA of the present invention.
- the non-human mammal deficient in expression of the DNA of the present invention lacks various biological activities that can be induced by the protein of the present invention, diseases caused by inactivation of the biological activity of the protein of the present invention. Since it can be a model, it is useful for investigating the causes of these diseases and studying treatment methods. '
- the non-human mammal deficient in DNA expression of the present invention can be used for screening for a compound having a therapeutic / preventive effect against diseases caused by deficiency or damage of the DNA of the present invention.
- the present invention is characterized by administering a test compound to a non-human mammal deficient in DNA expression of the present invention, and observing and measuring a change in the animal. It is intended to provide a method for screening a compound or a salt thereof having a therapeutic / preventive effect on a disease caused by the disease, for example, cancer.
- Examples of the non-human mammal deficient in DNA expression of the present invention used in the screening method include those described above.
- Test compounds include, for example, peptides, proteins, non-peptidic compounds, synthetic compounds, fermentation products, cell extracts, plant extracts, animal tissue extracts, plasma, etc. These compounds may be novel compounds or known compounds.
- a non-human mammal deficient in expression of the DNA of the present invention is treated with a test conjugate and compared with an untreated control animal, and changes in the organs, tissues, disease symptoms, etc. of the animal are observed.
- the therapeutic and prophylactic effects of the test compound can be tested using as an index.
- test compound for example, oral administration, intravenous injection and the like are used, and it can be appropriately selected according to the symptoms of the test animal, the properties of the test compound, and the like.
- the dose of the test compound can be appropriately selected according to the administration method, the properties of the test compound, and the like.
- cancer eg, colon, breast, lung, prostate, esophagus, stomach, liver, biliary tract, spleen, kidney, bladder, uterus, ovary, testis, thyroid, spleen
- a test compound is administered to a non-human mammal deficient in expression of the DNA of the present invention, and the test compound is administered to a non-administered group.
- the differences in the degree of onset of cancer and the degree of healing of cancer are observed over time in the above tissues.
- the disease symptom of the test animal is improved by about 10% or more, preferably about 30% or more, more preferably about 50% or more.
- the test compound can be selected as a compound having a therapeutic / preventive effect on the above-mentioned diseases.
- the compound obtained by using the screening method is a compound selected from the test compounds described above, and has a therapeutic / preventive effect on a disease caused by a deficiency or damage of the protein of the present invention. It can be used as a safe and low toxic prophylactic or therapeutic agent. Further, a compound derived from the compound obtained by the above-mentioned screening can also be used.
- the compound obtained by the Starry-Jung method may form a salt. Examples of the salt of the compound include physiologically acceptable acids (eg, inorganic acids, organic acids, etc.) and bases (eg, alkalis). A salt with a metal, etc.), and a physiologically acceptable acid addition salt is particularly preferable.
- salts examples include salts with inorganic acids (eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.), and organic acids (eg, acetic acid, formic acid, Salts with propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc. are used.
- inorganic acids eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.
- organic acids eg, acetic acid, formic acid
- Salts with propionic acid fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc.
- a drug containing the compound or a salt thereof obtained by the screening method can be produced in the same manner as the above-mentioned drug containing the protein of the present invention.
- the preparations obtained in this way are safe and low toxic, and can be used, for example, in humans or mammals (eg, rats, mice, guinea pigs, egrets, sheep, pigs, pigs, dogs, cats, dogs, Monkeys).
- the dose of the compound or a salt thereof varies depending on the target disease, the administration subject, the administration route, and the like.
- the compound when administered, it is generally used in adult (with a body weight of 60 kg) breast cancer patients.
- the single dose of the compound when administered parenterally, the single dose of the compound varies depending on the administration subject, target disease, and the like.
- the compound is usually administered in the form of an injection to an adult (assuming a body weight of 60 kg) breast cancer patients.
- the amount can be administered in terms of weight per 60 kg.
- the present invention relates to a compound that promotes or inhibits the activity of a promoter for the DNA of the present invention, which comprises administering a test compound to the non-human mammal deficient in expressing the DNA of the present invention and detecting the expression of a reporter gene. Or a method for screening for a salt thereof.
- the non-human mammal deficient in expressing DNA of the present invention may be a non-human mammal deficient in expressing DNA of the present invention, wherein the DNA of the present invention is inactive by introducing a reporter gene.
- a reporter gene that can be expressed under the control of a promoter for the DNA of the present invention is used.
- test compound examples include the same compounds as described above.
- reporter gene the same ones as described above can be used, and a galactosidase gene (1 ac Z), a soluble alkaline phosphatase gene or a luciferase gene is preferable.
- the tissue originally expressing the protein of the present invention may _Galactosidase is expressed in place of the protein. Therefore, the protein of the present invention can be easily prepared by staining with a reagent serving as a substrate for j3-galactosidase such as 5-bromo-4-chloro-3-indolyl-galactopyranoside (X-gal). Of the animal in vivo can be observed.
- a reagent serving as a substrate for j3-galactosidase such as 5-bromo-4-chloro-3-indolyl-galactopyranoside (X-gal).
- the protein-deficient mouse of the present invention or a tissue section thereof is fixed with glutaraldehyde or the like, washed with phosphate buffered saline (PBS), and then stained with X-ga1 at room temperature or at 37 ° C. After the reaction at about 30 ° C. for about 30 minutes to 1 hour, the / 3-galactosidase reaction may be stopped by washing the tissue specimen with an I mM EDTA / PBS solution, and the color may be observed. Further, mRNA encoding 1acZ may be detected according to a conventional method.
- PBS phosphate buffered saline
- the compound or a salt thereof obtained by the above-mentioned screening method is a compound selected from the test compounds described above, and is a compound that promotes or inhibits the promoter activity against DNA of the present invention.
- the compound obtained by the screening method may form a salt, and the salt of the compound may be a physiologically acceptable acid (eg, an inorganic acid, etc.) or a base (eg, an alkali metal, etc.) And the like, and particularly preferably a physiologically acceptable acid addition salt.
- a physiologically acceptable acid eg, an inorganic acid, etc.
- a base eg, an alkali metal, etc.
- Such salts include, for example, salts with inorganic acids (eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.) and organic acids (eg, acetic acid, formic acid, propionic acid, fumaric acid, Maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, Salts with benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc. are used. ,
- the compound of the present invention or a salt thereof that inhibits the promoter activity for DNA can inhibit the expression of the protein of the present invention and inhibit the function of the protein, it can be used for cancer (eg, colon cancer, breast cancer, lung cancer, Prostate cancer, esophageal cancer, stomach cancer, liver cancer, biliary tract cancer, spleen cancer, kidney cancer, bladder cancer, uterine cancer, ovarian cancer, testicular cancer, thyroid cancer, spleen cancer, brain tumor, blood tumor, etc.) Useful.
- cancer eg, colon cancer, breast cancer, lung cancer, Prostate cancer, esophageal cancer, stomach cancer, liver cancer, biliary tract cancer, spleen cancer, kidney cancer, bladder cancer, uterine cancer, ovarian cancer, testicular cancer, thyroid cancer, spleen cancer, brain tumor, blood tumor, etc.
- a drug containing a compound or a salt thereof obtained by the screening method can be produced in the same manner as the above-mentioned drug containing a protein of the present invention or a salt thereof.
- the preparations obtained in this way are safe and low toxic, and can be used, for example, in humans or mammals (eg, rats, mice, guinea pigs, egrets, sheep, pigs, pigs, dogs, cats, dogs, Monkeys).
- mammals eg, rats, mice, guinea pigs, egrets, sheep, pigs, pigs, dogs, cats, dogs, Monkeys.
- the dose of the compound or a salt thereof varies depending on the target disease, the subject of administration, the route of administration, and the like.
- the compound is administered daily at about 0.1 to 100 mg, preferably about 1.0 to 50 mg, more preferably about 1.0 to 20 mg.
- the single dose of the compound may vary depending on the administration subject, target disease, and the like.
- a dose calculated based on a body weight of 60 kg can be administered. It is extremely useful for screening a compound that promotes or inhibits or a salt thereof, and is useful for various diseases caused by insufficient DNA expression of the present invention. Investigating or preventing the cause ⁇ It can greatly contribute to the development of therapeutic agents.
- genes encoding various proteins are ligated downstream thereof and injected into egg cells of an animal to produce a so-called transgenic animal (gene transfer). Animal), it is possible to synthesize the protein specifically and examine its effects on living organisms. Furthermore, by linking an appropriate reporter gene to the above promoter portion and establishing a cell line in which this is expressed, a low-molecular-weight molecule having a function of specifically promoting or suppressing the production ability of the protein itself of the present invention in the body. Can be used as a search system for compounds.
- bases, amino acids, and the like are indicated by abbreviations based on the abbreviations by the IUPAC-IUB Commission on Biochemical Nomenclature or commonly used abbreviations in the art, and examples thereof are described below.
- amino acids may have optical isomers, the L-form is indicated unless otherwise specified.
- DNA Deoxylipo nucleic acid
- RNA Liponucleic acid
- mRNA messenger ribonucleic acid
- G 1 y glycine A 1 a: Alanine
- Th r Threonine
- Trt Trityl
- HOB t 1—Hydroxybenztriazole
- sequence numbers in the sequence listing in the present specification indicate the following sequences.
- SEMA 4 B having the amino acid sequence represented by SEQ ID NO: 4—encodes Ml This shows the base sequence of DNA.
- SEMA4B indicates the nucleotide sequence of DNA containing the full length gene encoding M3. [SEQ ID NO: 13]
- Example 1 shows the nucleotide sequence of a primer used in Example 1.
- Example 1 shows the nucleotide sequence of a primer used in Example 1.
- Example 1 shows the nucleotide sequence of a primer used in Example 1.
- Example 1 shows the nucleotide sequence of a primer used in Example 1.
- Example 1 shows the nucleotide sequence of a primer used in Example 1.
- Example 1 shows the nucleotide sequence of a primer used in Example 1.
- Example 1 shows the nucleotide sequence of a primer used in Example 1.
- Example 3 shows the nucleotide sequence of a primer used in Example 3.
- Example 3 shows the nucleotide sequence of a primer used in Example 3.
- T0P10 / SEMA4B- Ml / pCR4- T0P0 has been deposited with the National Institute of Advanced Industrial Science and Technology (AIST) at 1-1-1 Tsukuba-Higashi, Ibaraki Prefecture since March 4, 2003. It has been deposited with the Center under the accession number FERM BP-8316.
- TOPIO / SEMMB-M2 / pCR4-T0P0 has been deposited with the National Institute of Advanced Industrial Science and Technology (AIST) at 1-1-1 Tsukuba East Higashi, Ibaraki Prefecture since March 4, 2003 (postal code 305-8566). Deposited with the Center under the accession number FERM BP-8317.
- T0P10 / SEMA4B-M3 / pCR4 T0P0 was deposited on March 4, 2003 at Tsukuba-Higashi 1-chome, Ibaraki Pref. Deposited at the Center under the accession number FERM BP-8318.
- Semaphorin 4B Semaphorin 4B
- Semaphorin 4B-M3 Semaphorin 4B-M3
- a human non-small cell lung cancer cell line NCI-H1703 purchased from American Type Culture Collection (ATCC) was added to RPMI-1640 medium (containing 25 mM HEPES) (Invitrogen) with 10% fetal bovine serum (ATCC). And seeded on a 96-well flat-bottomed tissue culture plate (BD Falcon) at a cell density of 10,000 cells / well (medium volume 0.1 ml). After culturing overnight at 37 ° C. in a 5% carbon dioxide gas flow, the antisense oligonucleotide was transfected.
- ATCC American Type Culture Collection
- the 3 'untranslated region sequence of the protein having the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7, and SEQ ID NO: 10 is hybridized.
- SEQ ID NO: 13 After designing an antisense oligonucleotide sequence (SEQ ID NO: 13), a phosphorothioated oligonucleotide was synthesized, purified by HPLC, and used for an introduction experiment (hereinafter abbreviated as antisense oligonucleotide).
- control oligonucleotide As a control, the reverse sequence (SEQ ID NO: 14) of the nucleotide sequence represented by Rooster 3 column number: 13 was similarly phosphorothioated, purified by HPLC, and used (hereinafter abbreviated as control oligonucleotide).
- Oligofectamine (Invitrogen) diluted antisense oligonucleotide or control oligonucleotide diluted 5-fold with Opti-MEM (Invitrogen) and left at room temperature for 5 minutes And a ratio of 8: 3 (volume ratio), and applied to the plate at a rate of 40 ⁇ L per well.
- the final concentration of the oligonucleotide was adjusted to 250 nM.
- the apoptosis-inducing activity of the above two kinds of oligonucleotides was measured using Cell Death Detection ELISA PUK kit (Roche Diagnostics) according to the attached protocol.
- the antisense oligonucleotide (SEQ ID NO: 13) showed about 1.6 times the apoptosis-inducing activity compared to the control oligonucleotide (SEQ ID NO: 14), and showed a statistically significant difference (P ⁇ 0.01). ) (Table 3).
- Apoptosis inducing activity (A 4 5 -. A 492 ) Mean value Standard deviation
- Antisense oligonucleotide 0.538 0.035
- the human non-small cell lung cancer cell line NCI ⁇ 11703 used in Reference Example 2 was suspended in the same medium as in Reference Example 2, and a 24-well flat bottom tissue culture was performed at a cell density of 60,000 cells per medium (medium volume: 0.6 ml). Plates (BD Falcon) were seeded. 37. In a 5% carbon dioxide gas stream. After culturing in C, the antisense oligonucleotide was transfected according to the method of Reference Example 2.
- the addition amount of the oligonucleotide was 240 ⁇ l per square well, and two kinds of antisense oligonucleotides (SEQ ID NO: 13 and SEQ ID NO: 15) and two kinds of control oligonucleotides (SEQ ID NO: The oligonucleotides of SEQ ID NO: 14 and SEQ ID NO: 16) were used.
- SEQ ID NO: 15 After designing an antisense oligonucleotide sequence (SEQ ID NO: 15) that hybridizes to the 3, untranslated region sequence of the protein having the indicated amino acid sequence, a phosphorothioated oligonucleotide is synthesized and purified by HPLC. Used for introduction experiments.
- the reverse sequence (SEQ ID NO: 16) of the base sequence represented by SEQ ID NO: 15 was similarly phosphorothioated, purified by HPLC, and used.
- RNA was extracted using a R easy (registered trademark) Mini Total RA Kit (QIAGEN). Using about 300 ng of total RNA as type I, reverse transcription was carried out using TaqMan Reverse Transcription Reagents (Applied Biosystems) according to the attached protocol. To total RNA?
- the cDNA corresponding to ⁇ 9 ng was designated as type III, and two types of primers (SEQ ID NO: 17 and SEQ ID NO: 18) were used with SSY4 Green PCR Master Mix (Applied Biosystems) to obtain SEMA4B, SEMA4B-Ml, SEMA4B- The expression copy number of the M2 and SEMA4B-M3 genes was measured.
- the expression amount of the 3-actin gene contained in the same amount of type III cDNA was determined using TaqMan ⁇ -actin Control Reagents (Applied Biosystems) and used as an internal standard.
- control oral oligonucleotide (SEQ ID NO: 14 and SEQ ID NO: 16) administration groups were 4.1% and 3.4%, respectively, which were statistically significant compared to the non-transfection group. No significant decrease in the expression level was observed.
- a PCR reaction was performed using two types of primers (SEQ ID NO: 19 and SEQ ID NO: 20).
- the reaction solution 50 ⁇ 1, l J ul of the cDNA, 2. 5U PfuTurbo Hotstart DNA Polymerase (STRATAGENE Corp.), each 1. primer Omicron mu Micromax (SEQ ID NO: 1 9 and SEQ ID NO: 2 0),
- the composition contained 200 dNTPs and 25 ⁇ l 2x GC Buffer I (Takara Bio).
- the PCR reaction was repeated at 95 ° C for 1 minute, followed by 30 cycles of 95 ° C for 1 minute, 60 ° C for 1 minute, and 72 ° C for 4 minutes, followed by an extension reaction at 72 ° C for 5 minutes. .
- 5 U of Ex Taq DNA Polymerase (Takara Bio) was added and incubated at 72 ° C for 7 minutes.
- the obtained PCR reaction product was purified using a PCR Purification Kit (QIAGEN). This was subcloned into the plasmid vector pCR4-TOP0 (Invitrogen) according to the prescription of the T0P0TA PCR Cloning Kit (Invitrogen).
- SEMA4B gene (GenBank Accession No. M-0444533 gene; ⁇ _198925 gene; The base sequence represented by SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8 and SEQ ID NO: 11 SEQ ID NO: 3, SEQ ID NO: 6, SEQ ID NO: 9 and SEQ ID NO: 12 show the nucleotide sequences added to the 5 ′ end and 3 ′ end of the
- amino acid sequence (SEQ ID NO: 1) encoded by the nucleotide sequence represented by SEQ ID NO: 2 is completely identical to the SEMA4B protein encoded by the SEMA4B gene (GenBank Accession No. XM_044533 gene; Rei 198925 gene; ⁇ —020210 gene) Matched.
- SEMA4B-Ml is a protein containing the amino acid sequence (SEQ ID NO: 4) encoded by the nucleotide sequence represented by SEQ ID NO: 5, and an amino acid sequence encoding the nucleotide sequence represented by SEQ ID NO: 8
- the protein containing (SEQ ID NO: 7) is named SEMA4B-M2
- the protein containing the amino acid sequence (SEQ ID NO: 10) encoded by the nucleotide sequence represented by SEQ ID NO: 11 is named SEMA4B-M3, respectively. did.
- the 90th g of the DNA sequence (SEQ ID NO: 2) of the DNA encoding SEMA4B (SEQ ID NO: 2) corresponds to a
- the 111th g corresponds to a
- 623 The gth is replaced by t, respectively, and the 623th substitution is accompanied by an amino acid substitution.
- the 150th g of the base sequence of the DNA encoding SEMA4B is a
- the 489th g is a
- 528 The 1st c is replaced by t
- the 1266th t is replaced by c
- the 1588th c is replaced by a
- the 2343th a is replaced by g
- the 489th substitution is accompanied by an amino acid substitution.
- Lys at position 364 in the amino acid sequence of SEMA4B is substituted with Asn.
- SEMA4B / pCR4-T0P0 is a plasmid having the DNA having the nucleotide sequence represented by 2.
- SEQ ID NO: SEMA4B-Ml / pCR4-T0P0 is a plasmid having the DNA having the nucleotide sequence represented by SEQ ID NO: 5.
- SEMA4B-M2 / pCR4-T0P0 is a plasmid having the DNA having the nucleotide sequence represented by 8
- SEMA4B-M3 / pCR4-T0P0 is a plasmid having the DNA having the nucleotide sequence represented by SEQ ID NO: 11. I named each.
- the transformant having the plasmid SEMA4B / pCR4-T0P0 introduced therein was transformed with Escherichia coli T0P10 / SEMA4B / pCR4-T0P0, and the transformant having the plasmid SEMA4B-Ml / pCR4-T0P0 transformed with Escherichia coli T0P10 / SEMA4B-Ml.
- the PCR reaction was performed using the cDNA obtained from 3 to 4 ng of the total RNA as the ⁇ type under the same conditions as in Reference Example 3, and the SEMA4B, SEMA4B-Ml, SEMA4B-M2 and SEMA4B-M3 genes were The expression copy number was calculated.
- the copy number of the 3 / 3-actin gene contained in 1 ng of the total RNA was calculated and used as an internal standard.
- Table 4 shows the relative expression rates obtained by standardizing the expression level of the entire gene with the ⁇ -actin gene expression level.
- Plasmid SEMA4B / pCR4-T0P0 obtained in Reference Example 4 was used as type III, and the SEMA4B gene was ⁇ It was wide.
- the composition of the reaction solution used in the reaction was 2 ng of SEMA4B / pCR4-TOPO as type II, 2.5 U of Pfu Turbo Hotstart DNA Polymerase (STRATAGENE), two types of primers (SEQ ID NO: 19 and SEQ ID NO: 19). : 1) was added to each of 1 ⁇ , dNTPs was added to 200 ⁇ , and 10 x Pfu Buffer was added to 5 ⁇ to obtain a 50 ⁇ 1 solution.
- PCR reaction a cycle of 95 ° C for 1 minute, 95 ° C for 1 minute, 60 ° C for 1 minute, and 72 ° C for 4 minutes was repeated 25 times.
- the PCR reaction product was purified using PCR Purification Kit (QIAGEN), and then treated with restriction enzymes XbaI and EcoRI. Plasmid p3xFLAG-CMV-14 (Sigma) was also treated with XbaI and EcoRI. Each DNA fragment was purified using a PCR Purification Kit, and a ligation reaction was performed using DNA Ligation Kit ver. 2 (Takara Bio). After introducing the ligation reaction solution into E. coli T0P10, the transformed E.
- SEMA4B protein SEQ ID NO: 1
- SEMA4B-Ml protein SEQ ID NO: 4
- SEMA4B-M2 protein SEQ ID NO: 7
- SEMA4B-M3 protein SEQ ID NO: 10
- Asn-Ser-Ala-Arg-Glu-Arg-Lys-lie-Asn-Ser-Ser-Cys (SEQ ID NO: 22)] is the amino acid from position 402 to position 412 of the SEMA4B protein (SEQ ID NO: 1) This is a sequence obtained by adding Cys to the C-terminal of the sequence.
- Ser-Arg-Val-Phe-Thr-Glu-Ser-Glu-Lys-Arg-Pro-Leu-Ser-Cys is a SEMA4B protein (SEQ ID NO: 1) from position 797 to position 809. This is a sequence in which Cys has been added to the C-terminus of the amino acid sequence up to the first.
- KLH keyhole limpet to mosinin
- the immunized animal used one male male egret KBL: JW (11-week-old, Oriental yeast), the first sensitization was a complete Freund's adjuvant (Dco) suspension, and the second and subsequent times were incomplete Freund's adjuvant ( Difco) suspension was used.
- the sensitization was performed by subcutaneous injection on the back. One sensitization was performed using 0.5 mg of each antigen, and was repeated three times every 14 days after the first sensitization.
- the SEMA4B protein (SEQ ID NO: 1) was detected using the purified peptide antibody prepared in Reference Example 8.
- NCI-H358 cells derived from human non-small cell lung cancer were suspended in 10 ml of RPMI-1640 medium (Invitrogen) containing 10% fetal bovine serum (JRH) and placed in a 10 cm diameter dish. Seeded. The cells were cultured at 37 ° C under a 5% carbon dioxide gas stream.
- Plasmid pCMV-14 was produced in - SEMA4B 6 mu ⁇ and Plus reagent (Invitrogen) and 0PTI- MEM I (Invitrogen Corp.) were mixed and allowed to stand at room temperature for 15 minutes, LipofectAMINE trans Hue transfection reagent ( Invitrogen) and 0PTI-MEMI were added, and the mixture was further left at room temperature for 15 minutes. This mixture was dropped into the culture solution to continue the culture.
- the cells were washed with ice-cold PBS, and ice-cold RIPA buffer [50 IBM Tris.HCl buffer, pH 7.5, 150 raM sodium chloride, 1% Triton X-100, 0.1% % SDS, 1% deoxycornoleic acid, Complete TM tablet (Roche Diagnostics), Phosphatase Inhibitor Cocktail-2 (Sigma)], and left to stand at 4 ° C for 30 minutes.
- the RIPA buffer was recovered, and the supernatant obtained by centrifugation at 15, OOO rpm for 20 minutes was used as a cell-free extract.
- blocking solution such as a 3 mu concentration ⁇ / ⁇ 1, one at 4 ° C
- the reaction was performed overnight. Subsequently, it was left at room temperature for 1 hour in an HRP-labeled anti-Egret IgG antibody (Amersham-Bioscience) diluted 50,000-fold or 100,000-fold with a blocking solution.
- a cell-free extract was prepared in the same manner as in Reference Example 9.
- a cell-free extract 400 ⁇ l was added to a suspension (50 At 1) in which Protein G-Sepharose 4FF (Amersham-Bioscience) was suspended in an equal volume of RIPA buffer, and the peptide antibody AS-2531 described in Reference Example 8 , AS-2532, AS-2591 or AS-2592 was added to 5 g of the mixture, and the mixture was stirred at 4 ° C. overnight.
- SDS-PAGE sample buffer (62.5 ⁇ Tris' hydrochloric acid buffer, ⁇ 6.8, 20% glycerol, 2% SDS , 0.02% promophenol and 2.5% 2-mercaptoethanol), heat at 95 ° C for 5 minutes, and apply 5 ⁇ l or 10 / z 1 on a 10% acrylamide gel.
- SDS-PAGE sample buffer (62.5 ⁇ Tris' hydrochloric acid buffer, ⁇ 6.8, 20% glycerol, 2% SDS , 0.02% promophenol and 2.5% 2-mercaptoethanol), heat at 95 ° C for 5 minutes, and apply 5 ⁇ l or 10 / z 1 on a 10% acrylamide gel.
- Detection was based on the method described in Reference Example 9.
- HRP-labeled anti-mouse IgG antibody (Amersham) was prepared by diluting mouse anti-FLAG M2 antibody (Sigma) to 0.2 ⁇ g / ml or 0.2 g / ml with a blocking solution as the primary antibody. -Bioscience) diluted 50,000-fold or 50,000-fold with a blocking solution as a secondary antibody Using.
- Peptide antibodies AS-2531, AS- 2532, AS- when having conducted the immunoprecipitated with either 2591 and AS 7 2592 also a specific band resulting from SEMA4B protein near the molecular weight 100kD was observed.
- Lung cancer cell lines NCI-H2228, NCI-H1651, NCI-H358, NCI-H23 and NCI-HI 703; ovarian cancer cell lines SKOV-3 and TOV-21G; prostate cancer cell line DU145; and knee cancer cell line PANC- 1 was cultured in two Petri dishes having a diameter of 10 cm. One plate of each dish was dispersed with trypsin / EDTA (Invitrogen), and the number of cells was counted. Based on the number of cells counted, add 1 ml of ice-cold RIPA buffer (described in Reference Example 9) to 5 x 10 6 cells to the remaining one petri dish, and incubate at 4 ° C. Left for 30 minutes.
- trypsin / EDTA Invitrogen
- the RIPA buffer was recovered, and the supernatant obtained by centrifugation at 15, OOO rpm for 20 minutes was used as a cell-free extract.
- a resin prepared by crosslinking the peptide antibody AS-2531 described in Reference Example 8 with ProteinG-Sepharose 4FF (Amersham-Bioscience) was prepared. Suspended in buffer. 400 ⁇ l of the above-mentioned cell-free extract was added to the suspension 301, followed by stirring at 4 ° C.
- the ProteinG-Sepharose 4FF coprecipitated fraction was washed with RIPA buffer, suspended in the sample buffer 301 for SDS-PAGE described in Reference Example 10, heated at 95 ° C for 5 minutes, and 20 ⁇ l was added to 10% The samples were subjected to SDS-PAGE on an acrylamide gel. Detection was performed according to the method described in Reference Example 9 using the peptide antibody AS-2532.
- NEMA-H2228, NCI-H358, NCI-H23, SKOV-3, DU145 and PANC-1 are derived from SEMA4B protein with a molecular weight of around 100 kD in each cell line. Specific bands were observed. This revealed that the SEMA4B protein was highly expressed in the above six types of cancer cell lines.
- NCI-H358 cells derived from human non-small cell lung cancer were suspended in 2 ml of RPMI-1640 medium (Invitrogen) containing 10% fetal calf serum (JRH), ImM sodium pyruvate and 25 mM HEPES. After seeding on a 6-well plate, the cells were cultured at 37 ° C. under a 5% carbon dioxide gas stream.
- the cells recovered from the other well were diluted to 0.7 cells per well, and then seeded on a 96-well plate.
- the culture was continued at 37 ° C. in a 5% carbon dioxide gas flow while changing the G418 selection medium every 3 or 4 days until the cell density reached about 50%.
- inoculate 2 ⁇ l of the 48 ⁇ l plate continue culturing until the cell density becomes 50% or more, and use the cell lysate prepared from 1 ⁇ l of cells as described above for Western blotting.
- a clone that highly expressed the SEMA4B protein (SEQ ID NO: 1) was selected, and a cell line SEMA4B / H358 that stably expressed SEMA4B was obtained.
- SEQ ID NO: 1 A clone that highly expressed the SEMA4B protein (SEQ ID NO: 1) was selected, and a cell line SEMA4B / H358 that stably expressed SEMA4B was obtained.
- Reference Example 1 3 A clone that highly expressed the
- the human non-small cell lung cancer cell lines NCI-H2228 and NCI-H358 and SEMA4B / H358 described in Reference Example 12 were each seeded on a 10 cm diameter Petri dish and cultured until they became subconfluent. After each cell was washed with PBS, PBS containing 0.5% BSA and 5 mM EDTA was added, and the mixture was left at room temperature for 15 minutes to disperse the cells. Next, buffer A (HBSS (Hanks' Balanced Salt Solutions, Invitrogen) containing 2% fetal bovine serum (JRH) and 0.1% sodium azide) was used to a concentration of 4 ⁇ 10 6 cells / ml.
- buffer A HBSS (Hanks' Balanced Salt Solutions, Invitrogen) containing 2% fetal bovine serum (JRH) and 0.1% sodium azide
- AS-2532 or non-immune rabbit (Jackson) was added to a final concentration of 10 g / ml and left on ice for 3 hours.
- the cells were suspended in buffer A containing 10 ⁇ g / ml of Alexa488-labeled anti-Peacock IgG antibody (Molecular Probes), and left on ice for 2 hours.
- analysis was performed using FACScan (BD Biosciences). As a result, all cells were stained specifically for the rabbit antibody AS-2532, and the SEMA4B, SEMA4B-Ml, SEMA4B-M2 and SEMA4B-M3 proteins were localized on the cell surface. Became clear.
- NCI H3 5 8 10% fetal bovine serum (JRH Co.), was suspended NCI H3 5 8 with ImM containing sodium pyruvate and 25 niM HEPES RPMI- 1640 medium (Invitrogen), 1 Ueru per 8 X 10 3 cells density ( so that a medium liquid amount 80 mu 1), the NCI-H3 5 8 were seeded in 9 6-well flat bottom tissue culture plates (BD Falcon) in a 5% carbon dioxide gas flow to 37 ° C De ⁇ culture.
- ImM containing sodium pyruvate 25 niM HEPES RPMI- 1640 medium (Invitrogen), 1 Ueru per 8 X 10 3 cells density ( so that a medium liquid amount 80 mu 1)
- the NCI-H3 5 8 were seeded in 9 6-well flat bottom tissue culture plates (BD Falcon) in a 5% carbon dioxide gas flow to 37 ° C De ⁇ culture.
- Apoptosis inducing activity (A 4 5 -. A 492 ) Mean value Standard deviation
- Antisense oligonucleotide 0.467 0.029
- NCI-H1703 Reference Example 2
- NCI H 35 8 human non-small cell lung cancer cell lines Example 15
- apoptosis was examined whether induced by antisense oligonucleotides introduced.
- RPMI-1640 medium (Invitrogen) containing 10% fetal calf serum (JRH), ImM sodium pyruvate and 25 mM HEPES was used for NCI-H2228.
- ACL-4 medium (ATCC) containing 10% FBS was used for NCI-H1651.
- RPMI-1640 medium (Invitrogen) containing 10% fetal calf serum (JRH) and 25 mM HEPES was used.
- Each cell was suspended in the culture medium of their respective, 7.5 ⁇ 10 3 cells per Uweru (NCI- H2228), 7.5X10 3 pieces (NCI-H1651) and 5X10 3 cells (NCI - H23) cell density (medium solution (Amount of 125 ⁇ ) was seeded on a 96-well flat bottom tissue culture plate (BD Falcon) and cultured overnight at 37 ° C in a 5% carbon dioxide gas stream.
- medium solution Amount of 125 ⁇
- the antisense oligonucleotide described in Reference Example 2 (SEQ ID NO: 13) and the control oligonucleotide (SEQ ID NO: 14) / zg was diluted with OPTI-MEM I (Invitrogen), mixed with Plus reagent (Invitrogen) 0.751, and left at room temperature for 15 minutes.
- OPTI-MEM I Invitrogen
- Plus reagent Invitrogen
- 4 / x1 of LipofectAMINE transfection reagent (Invitrogen) diluted with 0PTI-MEM I. was added and left at room temperature for 15 minutes.
- the apoptosis-inducing activity of the above oligonucleotide was measured according to the protocol attached to Cell Death Detection ELISA PLUS (Roche Diagnostics).
- the antisense oligonucleotide was 1.58 times (NCI-H2228), 1.21 times (NCI-H1651) and 1.25 times (NCI-H23) compared to the control oligonucleotide used as a negative control. ),
- the risk factors were calculated as P ⁇ 0.05 (NCI-H2228), P ⁇ 0.05 (NCI-H1651) and P ⁇ 0.01 (NCI-H23), indicating a statistically significant difference. (Table 7, Table 8, and Table 9)
- Apoptosis-inducing activity (A 405 — A 492 ) Mean standard deviation
- Apoptosis induction activity (A 405 _A 492 ) Mean standard deviation
- Cis induction activity (A 405 — A 492 ) Mean standard deviation
- Antisense oligonucleotides 1.351 0.058
- the human non-small cell lung cancer cell line NCI-H2228 was obtained in Reference Example 8.
- the cells were treated with AS-2531 and AS-2532, and the apoptosis-inducing activity of these rabbit antibodies was measured. .
- the cells were suspended in RPMI-1640 medium (Invitrogen) containing HEPES, and seeded on a 96-well flat bottom tissue culture plate (BD Falcon) coated with type I collagen to a cell density of 4 ⁇ 10 3 cells / cell.
- the cells were cultured overnight at 37 ° C in a 5% carbon dioxide gas stream.
- the egret peptide antibodies AS-2531 and AS-2532 obtained in Reference Example 8 and the non-immune egret IgG (Jackson) were diluted with PBS, and the final concentration of each antibody was 15 ⁇ g / ml, 45 g / ml and 150 ⁇ g / ml. ⁇ g / ml was added to each culture. After culturing was further continued for 5 days, the apoptosis-inducing activity of the above-mentioned sagi peptide antibody was measured according to the protocol attached to Cell Death Detection ELISA PLUS (Roche Diagnostics).
- SEMA4B protein SEMA4B-Ml protein
- SEMA4B-M2 protein SEMA4B-M3 protein
- PlexinBl cDNA was obtained by PCR.
- the composition of the reaction solution was prepared by using the above cDNA 11 as type II, 1.25 U of Pfu Turbo DNA Polymerase (STRATAGENE), and two kinds of primers (SEQ ID NO: 27 and SEQ ID NO: 28). ) was added to each of 2 ⁇ ⁇ , dNTPs at 200 / ⁇ ⁇ , and 2x GC Buffer I (Takara Bio) for ⁇ ⁇ ⁇ ⁇ ⁇ to give a volume of 20 ⁇ l.
- each PCR reaction product was separated on a 0.8% agarose gel prepared by adding crystal violet to 1.6 / zg / ml, and the MinElute Gel Extraction Kit ( (QIAGEN).
- pCR-XL-PLXNB1-NT was co-digested with two types of restriction enzymes (EcoRI and SnaBI) to obtain a DNA fragment of about 2 kbp (DNA fragment-1).
- pCR-XL-PLXNB1-CT was co-digested with three kinds of restriction enzymes (SnaBI, Dral and Xbal) to obtain a DNA fragment of about 4. lkbp (DNA fragment-2).
- pcDNA3.1 (+) plasmid Invitrogen
- DNA fragment-1, DNA fragment-2 and DNA fragment-3 were separately purified using MinElute Gel Extraction Kit, and then mixed at a volume ratio of 2: 2: 1 to obtain 5 ⁇ 1. Further, 5 ⁇ l of solution I of DNA Ligation Kit ver. 2 (Takara Bio) was added and reacted at 16 ° C. for 30 minutes. Then, 2 ⁇ l was extracted and E. coli T0P10 was transformed. Analyze the sequence of individual clones and use the full-length PlexinBl cDNA A plasmid (pcDNA3.1 (+)-PLX Bl-NT2) containing a cDNA fragment corresponding to positions -95 to 5840 of the above was obtained. ,
- a PCR reaction was performed using the above plasmid (pcDNA3.1 (+)-PLXNB1-NT2) as type III.
- the reaction composition in this reaction was as follows: 10 ng of the above plasmid, 1.25 U of Pfu Turbo DNA Polymerase, 1 ⁇ of each of the two primers (SEQ ID NO: 31 and SEQ ID NO: 32), and 200 ⁇ L of dTPs. ⁇ Add 2x GC Buffer I ( ⁇ ) to make a volume of 20 ⁇ 1.
- the PCR reaction is repeated at 95 ° C for 1 minute, followed by a cycle of 95 ° C for 30 seconds, 65 ° C for 30 seconds, 72 ° C for 5 minutes 30 times, followed by a reaction at 72 ° C for 7 minutes.
- PCR reaction products were separated on 0.8% Agaro Sugeru was ⁇ Ka ⁇ so that crystal violet and 1 ⁇ 6 ⁇ ⁇ / ⁇ 1, MinElute Gel Extraction Kit and the DNA of length of 4 ⁇ 5kbp Purified using This was subcloned into the plasmid vector pCR-XL-T0P0, introduced into E. coli T0P10, and then selected in LB agar medium containing kanamycin.
- the total length of PlexinBl was determined according to the prescription of the QuikChange Site-Directed Mutagenesis Kit (STRATAGENE). T at the 3483rd position of the cDNA was converted to C, and a plasmid pCR-XL-PLXNB1-ECD-Ml into which a silent mutation was introduced was prepared. On the other hand, the constant (Fc) region of human immunoglobulin was added to the C-terminus. To express the extracellular region of PlexinBl as a protein, the human Fc region was amplified by PCR.
- the composition of the reaction solution was as follows: Human spleen-derived cDNA (MTC Panel, BD CLONTECH), 11, Pfu Turbo DNA Polymerase, 1.25 U, and two types of primers (SEQ ID NO: 33 and SEQ ID NO: 34), 0.5 ⁇ each. ⁇ , 200 / ⁇ of dNTPs, and 10 ⁇ l of 2x GC Buffer I were added to make a liquid volume of 20 ⁇ l.
- the cycle of 95 ° C for 30 seconds, 65 ° C for 30 seconds, 72 ° C for 1 minute is repeated 30 times, and the reaction at 72 ° C for 7 minutes is further performed. Added.
- PCR reaction product The product was purified using the MinElute PCR Purification Kit (QIAGEN) and subcloned into a plasmid vector pCR4-TOP0 (Invitrogen).
- the transformed Escherichia coli T0P10 was selected on an LB agar medium containing kanamycin, and the sequence of each clone was analyzed. As a result, a plasmid pCR4-TOP0-Fc containing a cDNA fragment encoding the human Fc region was obtained.
- pCR4-TOP0-Fc was co-digested with two types of restriction enzymes (BamHI and Hindi II) to obtain a DNA fragment of about 0.7 kbp (DNA fragment-4).
- the aforementioned pCR-XL-PLXNB1-ECD-Ml was digested with BamHI to obtain a DNA fragment of about 4.5 kbp (DNA fragment-5).
- pcDNA3.1 (-) plasmid (Invitrogen) was co-digested with two types of restriction enzymes (BamHI and Hindlll) to obtain a DNA fragment of about 5.4 kbp (DNA fragment-6).
- DNA fragment-4, DNA fragment-5 and DNA fragment-6 were separately purified using MinElute Gel Extraction Kit, and then mixed at a volume ratio of 2: 2: 1 to 5 ⁇ l. 5 ⁇ l of Solution I of DNA Ligation Kit ver. 2 was added, and allowed to react at ⁇ 16 ° C., 2 ⁇ l was extracted, and Escherichia coli T0P10 was transformed. Analysis of individual clones selected on LB agar medium containing ampicillin revealed that plasmid pcDNA3.1 (-)-PLXNB1-ECD, which can express PlexinBl chimeric protein with the human Fc region linked to the C-terminal side / Fc.
- the human fetal kidney-derived cell line HEK293 (1.5 ⁇ 10 6 cells) described in Reference Example 5 was suspended in 10 ml of DMEM medium (Invitrogen) containing 10% fetal bovine serum (JRH), and type I collagen was After seeding on a 10 cm diameter dish (BD Falcon) coated with E. coli, the cells were cultured overnight at 37 ° C. in a 5% carbon dioxide gas stream.
- DMEM medium Invitrogen
- JRH fetal bovine serum
- type I collagen After seeding on a 10 cm diameter dish (BD Falcon) coated with E. coli, the cells were cultured overnight at 37 ° C. in a 5% carbon dioxide gas stream.
- Example 1 The plasmid pcDNA3.1 (-)-PLXB1-ECD / Fc6ig obtained in _ (2) was diluted with 0PTI-MEMI (Invitrogen) to 200, and the FuGENE6 transfection reagent was used.
- the plasmid pCMV-14-SEMA4B-3xFLAG (described in Reference Example 7) was transfected into the human non-small cell lung cancer cell line NCI-H358 to prepare a cell-free extract.
- Example 11 A mixture of PLXNBl / Fc 200 / zl prepared in (3) or 200 ⁇ l of the negative control and 250 ⁇ l of the above cell-free extract was prepared, and the protein G described in Reference Example 10 was prepared. 50 ⁇ l of -Sepharose 4FF (Amersham-Bioscience) suspension was added, and the mixture was stirred at 4 ° C for a while.
- the Protein G-Sepharose 4FF coprecipitated fraction was washed with RIPA buffer (described in Reference Example 9) and suspended in 50 sample buffers for SDS-PAGE (described in Reference Example 9). After heating at 95 ° C for 5 minutes, 20 ⁇ l was subjected to SDS-PAGE on a 7.5% acrylamide gel.
- the AS-2591 antibody (described in Reference Example 8) was diluted to 3 g / ml with the blocking solution described in Reference Example 9, or a mouse anti-FLAG M2 antibody (Sigma) was added to the blocking solution described above. The solution diluted to 2 ⁇ g / ml was used as the primary antibody.
- the human embryonic kidney-derived cell line HEK293 (2 ⁇ 10 6 cells) described in Reference Example 5 was suspended in 10 ml of DMEM medium (Invitrogen) containing 10% fetal bovine serum (JRH), and the diameter coated with type I collagen was used. After seeding on lOcni's Petri dish (Iwaki Glass Co., Ltd.), the cells were cultured overnight at 37 ° C under 5% carbon dioxide gas flow.
- PlexinBl / Fc fusion protein stably expressing HEK293 cell line PLX B1-Fc / HEK293
- Example 2 PLXNB1-Fc / HEK293 obtained in (1) was suspended in 10 ml of DMEM medium (Invitrogen) containing 10% fetal bovine serum (JRH), and a type I collagen-coated 10 cm diameter Petri dish was suspended. After seeding on a dish (Iwaki Glass Co., Ltd.), the cells were cultured overnight at 37 ° C under a 5% carbon dioxide gas stream. The next day, the cells were washed with PBS, replaced with 10 ml of Ml "medium (Invitrogen) containing non-essential amino acids (Invitrogen) and ITS-X supplements (Invitrogen), and the culture was continued for another two days.
- DMEM medium Invitrogen
- JRH fetal bovine serum
- the culture solution is filtered through a 0.45 ⁇ filter (BD Falcon), and the molecular weight cutoff is approximately ⁇ ) using an ultra-concentrator ⁇ , ( ⁇ .
- This concentrated solution was named PLX Bl / Fc (lot No. 2) and used for the following studies:
- Each cell was seeded in a Petri dish (BD Falcon) with a diameter of 10 cm and cultured until it became subconfluent. Was washed with PBS, PBS containing 0.25% BSA and 2.5 mM EDTA was added, and the cells were allowed to stand at room temperature for 15 minutes to disperse the cells, containing 50 ⁇ l of the aforementioned PLXNBl / Fc (lot No. 2). 3 ⁇ 10 6 cells were suspended in 2 ⁇ 0 ⁇ l buffer ⁇ (described in Reference Example 14) prepared as described above, and left to stand for 3 hours on ice.
- the recombinant SEMA4B protein is located in the extracellular domain of SEMA4B and its C-terminal.
- a vector was constructed to express a protein tagged with FLAG-tag or 6 x His-tag, and a protein expression system was constructed using BAC-TO-BAC Baculovirus Expression System (Invitrogen).
- BAC-TO-BAC Baculovirus Expression System Invitrogen.
- PCR reaction was repeated at 94 ° C for 30 seconds, 60 ° C for 30 seconds, and 72 ° C for 3 minutes for 30 cycles.
- the PCR products were separated by agarose gel electrophoresis, collected using the QIAquick Gel Extraction Kit (QIAGEN), cloned into pCR2.1-TOP0 (Invitrogen), and cloned into pCR2.1 / SEMA4B-FLAG and pCR2.1 / SEMA4B. -Got His. After confirming the nucleotide sequence, pCR2.
- 1 / SEMA4B-FLAG and P CR2. 1 / SEMA4B- His a were simultaneously digested out with EcoR I (Takara Bio Inc.) and Hind III (Takara Bio Inc.), respectively, ⁇ moth Rosugeru electric
- the gel was electrophoresed, and the DNA digestion fragment was recovered using the QIAquick Gel Extraction Kit.
- pFASTBACl Invitrogen
- a ligation reaction was performed using Ligation High (Toyobo), and a beta-pFB / SEMA-FLAG with FLAG-tag added to the C-terminal or a vector pFB / SEMA-His with 6 XHis-tag added to the C-terminal was prepared.
- Ligation High Toyobo
- a beta-pFB / SEMA-FLAG with FLAG-tag added to the C-terminal
- a vector pFB / SEMA-His with 6 XHis-tag added to the C-terminal was prepared.
- Example 3_ (1) Using the recombinant SEMA4B-FLAG protein prepared in Example 3_ (1) as an immunogen, a rabbit heron polyclonal antibody was prepared. Emulsion prepared by mixing equal amounts of PBS solution of SEMA4B-FLAG protein and complete adjuvant in Freund was added to rabbits (Japanese white, female, 3 kg). Immunized with protein / one bird. For the second and subsequent immunizations, protein emulsions replaced with Freund's incomplete adjuvant were prepared in the same manner, and booster immunizations were repeated seven times every two weeks.
- Pre-immunization 4th and 6th immunization One week after the immunization, blood was collected from the ear vein and an increase in serum antibody titer was confirmed by ELISA using an immunoplate coated with SEMA4B-FLAG protein. One week after the final immunization, blood under anesthesia was collected from three puppies under anesthesia, and 65.1 ml from No. 1 puppies, 79.5 ml from No. 2 puppies, and 68.0 from No. 4 puppies. ml of antiserum was obtained.
- the recombinant SEMA4B-His protein described in Example 3 (1) was purified using HiTrap NHS-Activated HP (Amersham-Bioscience). Was adsorbed on an antigen column immobilized in the company. After washing the column with PBS, the column was eluted with 0.1 M Glycine-HC1 / 0.15 M NaCl '(pH 3) . The eluate was neutralized with 1 M Tris-HCl (pH 8). Dialysis at 4 ° C overnight. Anti-SEMA4B polyclonal antibody was purified and obtained.
- PlexinBl binding activity obtained in the presence of non-immune egret IgG was defined as 100%, and the binding inhibitory activity of the above-mentioned egret anti-SEMA4B polyclonal antibody was calculated.
- the median of the obtained fluorescence intensities was used for the calculation of PlexinBl binding activity.
- the NCI-H358 cell line described in Reference Example 5 or the SEMA4B / H358 cell line described in Reference Example 12 was transformed into an RPMI-1640 medium (Invitrogen) containing 1% fetal calf serum (JRH), ImM sodium pyruvate and 25 mM HEPES. ) And seeded on a 96-well flat bottom tissue culture plate (BD Falcon) at a cell density of 5 ⁇ 10 3 cells / ⁇ l. At the same time as the seeding, the rabbit herb anti-SEMA4B polyclonal antibody No. 1, No. 2, No.
- Example 4 or the non-immune rabbit herb IgG (Jackson) obtained in Example 3 (2) was used at a final concentration of 1 g / ml, 10 The mixture was added at z g / ml or 100 ⁇ g / ml and cultured at 37 ° C. for 6 days in a 5% carbon dioxide gas stream. After the completion of the culture, 20 ⁇ l of Cell Counting Kit-8 (Dojindo) was added, and the mixture was reacted at 37 ° C. for 90 minutes in a 5% carbon dioxide gas stream. Then, the difference in absorbance at 450 nm and 620 nm was measured. Using the absence of the antibody as a negative control, the cell proliferation inhibitory activity of the above-mentioned Egret polyclonal antibody was calculated.
- Non-immune rabbits did not show statistically significant growth inhibitory activity on either cell line (Table 10, Table 11), indicating that the growth inhibitory activity was specifically induced by SEMA4B It became clear.
- a protein containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7, or SEQ ID NO: 10 according to the present invention (the present invention)
- an antibody having an activity of neutralizing the stimulation of cancer cell proliferation brought about by the binding of the protein to the receptor is, for example, a cancer (eg, colon Pain, breast cancer, lung cancer, prostate cancer, esophageal cancer, stomach cancer, liver cancer, biliary tract cancer, spleen cancer, kidney cancer, bladder cancer, uterine cancer, ovarian cancer, testicular cancer, thyroid cancer, knee cancer, brain tumor, Agent for the prophylaxis or treatment of liquid tumors, etc.), apoptosis promoters
- a cancer eg, colon Pain, breast cancer, lung cancer,
- the quality preferably, a neutralizing active antibody etc.
- cancer eg, colon cancer, breast cancer, lung cancer, prostate cancer, esophagus cancer, stomach cancer, liver cancer, biliary tract cancer, spleen cancer, kidney cancer, bladder cancer, uterus
- It can be safely used as a preventive / therapeutic agent for cancer, ovarian cancer, testicular cancer, thyroid cancer, thyroid cancer, brain tumor, blood tumor, etc., a cancer cell apoptosis promoter, a cancer cell growth inhibitor, etc. .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005516538A JPWO2005061704A1 (ja) | 2003-12-24 | 2004-12-22 | 癌の予防・治療剤 |
EP04808074A EP1712619A4 (en) | 2003-12-24 | 2004-12-22 | SUBSTANCE FOR THE PREVENTION AND TREATMENT OF CANCER |
CA002551546A CA2551546A1 (en) | 2003-12-24 | 2004-12-22 | Preventive/remedy for cancer |
US10/584,183 US20070275888A1 (en) | 2003-12-24 | 2004-12-24 | Preventive/Remedy for Cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003427782 | 2003-12-24 | ||
JP2003-427782 | 2003-12-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005061704A1 true WO2005061704A1 (ja) | 2005-07-07 |
Family
ID=34708909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/019724 WO2005061704A1 (ja) | 2003-12-24 | 2004-12-22 | 癌の予防・治療剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20070275888A1 (ja) |
EP (1) | EP1712619A4 (ja) |
JP (1) | JPWO2005061704A1 (ja) |
CA (1) | CA2551546A1 (ja) |
WO (1) | WO2005061704A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013038907A1 (ja) * | 2011-09-14 | 2013-03-21 | 日本化薬株式会社 | 細胞の増殖抑制方法、nek10バリアント遺伝子に対するrna干渉作用を有する核酸分子、及び抗癌剤 |
JP2018521062A (ja) * | 2015-06-29 | 2018-08-02 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | B1sp融合タンパク質の治療薬、方法、および使用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2730441C (en) * | 2008-07-30 | 2019-04-16 | Jiten Odhavji Dihora | Encapsulated benefit agents and compositions requiring reduced levels of scavenger materials |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000012708A2 (en) * | 1998-09-01 | 2000-03-09 | Genentech, Inc. | Further pro polypeptides and sequences thereof |
WO2000078961A1 (en) * | 1999-06-23 | 2000-12-28 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2001036440A1 (en) * | 1999-11-19 | 2001-05-25 | Human Genome Sciences, Inc. | 23 human secreted proteins |
WO2001068848A2 (en) * | 2000-03-01 | 2001-09-20 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2001077137A1 (en) * | 2000-04-12 | 2001-10-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2002006329A2 (en) * | 2000-07-18 | 2002-01-24 | Curagen Corporation | Human polynucleotides and polypeptides encoded thereby |
WO2002046465A2 (en) * | 2000-12-08 | 2002-06-13 | Oxford Biomedica (Uk) Limited | Method for identification of genes involved in specific diseases |
WO2002052005A1 (fr) * | 2000-12-22 | 2002-07-04 | Kazusa Dna Research Institute Foundation | Genes et proteines codees par ceux-ci |
WO2004058817A1 (ja) * | 2002-12-26 | 2004-07-15 | Takeda Pharmaceutical Company Limited | 新規タンパク質およびその用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7073800A (en) * | 1999-08-25 | 2001-03-19 | Regents Of The University Of California, The | Novel plexins and uses thereof |
JP3787473B2 (ja) * | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | セマフォリン受容体 |
EP1365018A1 (en) * | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
-
2004
- 2004-12-22 WO PCT/JP2004/019724 patent/WO2005061704A1/ja active Application Filing
- 2004-12-22 JP JP2005516538A patent/JPWO2005061704A1/ja active Pending
- 2004-12-22 CA CA002551546A patent/CA2551546A1/en not_active Abandoned
- 2004-12-22 EP EP04808074A patent/EP1712619A4/en not_active Withdrawn
- 2004-12-24 US US10/584,183 patent/US20070275888A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000012708A2 (en) * | 1998-09-01 | 2000-03-09 | Genentech, Inc. | Further pro polypeptides and sequences thereof |
WO2000078961A1 (en) * | 1999-06-23 | 2000-12-28 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2001036440A1 (en) * | 1999-11-19 | 2001-05-25 | Human Genome Sciences, Inc. | 23 human secreted proteins |
WO2001068848A2 (en) * | 2000-03-01 | 2001-09-20 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2001077137A1 (en) * | 2000-04-12 | 2001-10-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2002006329A2 (en) * | 2000-07-18 | 2002-01-24 | Curagen Corporation | Human polynucleotides and polypeptides encoded thereby |
WO2002046465A2 (en) * | 2000-12-08 | 2002-06-13 | Oxford Biomedica (Uk) Limited | Method for identification of genes involved in specific diseases |
WO2002052005A1 (fr) * | 2000-12-22 | 2002-07-04 | Kazusa Dna Research Institute Foundation | Genes et proteines codees par ceux-ci |
WO2004058817A1 (ja) * | 2002-12-26 | 2004-07-15 | Takeda Pharmaceutical Company Limited | 新規タンパク質およびその用途 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1712619A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013038907A1 (ja) * | 2011-09-14 | 2013-03-21 | 日本化薬株式会社 | 細胞の増殖抑制方法、nek10バリアント遺伝子に対するrna干渉作用を有する核酸分子、及び抗癌剤 |
JPWO2013038907A1 (ja) * | 2011-09-14 | 2015-03-26 | 日本化薬株式会社 | 細胞の増殖抑制方法、nek10バリアント遺伝子に対するrna干渉作用を有する核酸分子、及び抗癌剤 |
JP2018521062A (ja) * | 2015-06-29 | 2018-08-02 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | B1sp融合タンパク質の治療薬、方法、および使用 |
JP2021180671A (ja) * | 2015-06-29 | 2021-11-25 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | B1sp融合タンパク質の治療薬、方法、および使用 |
JP7193590B2 (ja) | 2015-06-29 | 2022-12-20 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | B1sp融合タンパク質の治療薬、方法、および使用 |
Also Published As
Publication number | Publication date |
---|---|
CA2551546A1 (en) | 2005-07-07 |
EP1712619A1 (en) | 2006-10-18 |
US20070275888A1 (en) | 2007-11-29 |
JPWO2005061704A1 (ja) | 2007-07-12 |
EP1712619A4 (en) | 2008-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005097204A1 (ja) | 癌の予防・治療剤 | |
WO2007004692A1 (ja) | 非小細胞肺がんの予防・治療剤および診断薬 | |
JP5704722B2 (ja) | 細胞接着阻害剤およびその用途 | |
WO2006093337A1 (ja) | 癌の予防・治療剤 | |
WO2007018316A1 (ja) | 癌の予防・治療剤 | |
US20100008926A1 (en) | Novel proteins and use thereof | |
WO2005061704A1 (ja) | 癌の予防・治療剤 | |
WO2003055506A1 (fr) | Medicaments pour la prevention et le traitement du cancer | |
WO2007010628A1 (ja) | 癌の予防・治療剤 | |
JP4530631B2 (ja) | 新規タンパク質および癌の予防・治療剤 | |
WO2004048565A9 (ja) | アポトーシス関連蛋白質およびその用途 | |
JP2004222539A (ja) | 新規な癌遺伝子、該癌遺伝子由来の組換えタンパク質、およびそれらの用途 | |
JP4353697B2 (ja) | がんの予防・治療剤 | |
JP2004217634A (ja) | がんの予防・治療剤 | |
WO2002033071A1 (fr) | Polypeptides analogues a la survivine et leurs adn | |
WO2006101273A1 (ja) | 癌の予防・治療剤 | |
WO2004002514A1 (ja) | 癌の予防・治療剤 | |
WO2004018678A1 (ja) | 癌の予防・治療剤 | |
JP2004290177A (ja) | 新規タンパク質およびその用途 | |
JP2003189873A (ja) | がんの予防・治療剤 | |
JP2004089182A (ja) | がんの予防・治療剤 | |
JP2001299364A (ja) | 新規タンパク質およびそのdna | |
JP2004105171A (ja) | 癌の予防・治療剤 | |
JP2004075569A (ja) | Il20受容体およびil20の新規用途 | |
WO2004058969A1 (ja) | がんの予防・治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005516538 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004808074 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2551546 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2004808074 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10584183 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10584183 Country of ref document: US |